Aryl-phosphorus-oxygen compound as EGFR kinase inhibitor

Abstract

Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.

Description

ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR This application claims the following priority to: CN201710592778.X, application date 2017, 07.19; CN201711277584.7, application date 2017, 12.06; CN201810130633.2, application date 2018, 02.08; and CN201810355614.X, application date 2018, 04.19. FIELD OF THE INVENTION The present application relates to an aryl-phosphine-oxygen compound as an EGFR kinase inhibitor, and specifically discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. BACKGROUD OF THE INVENTION Lung cancer is one of the most common malignant tumors. There will be about 1.6 million new cases of lung cancer cases each year worldwide, and there will be 1.4 million deaths from lung cancer each year. Among them, non-small cell lung cancer (NSCLC) accounts for about 80%-85% of all lung cancers (the 10th Lung Cancer Summit Forum). EGFR (epidermal growth factor receptor)-TKI (tyrosine kinase inhibitor), as a small molecule inhibitor, competitively binds to EGFR with endogenous ligands and inhibits activation of tyrosine kinase, resulting in blocking the EGFR signaling pathway, and ultimately producing a series of biological effects such as inhibiting tumor cell proliferation and metastasis, and promoting tumor cell apoptosis, and it is one of the main targets for lung cancer treatment. Osimertinib (AZD9291) is a third-generation EGFR-TKI-targeted drug. Although it has higher responsivity to drug resistance caused by T790M mutation, patients also develop drug resistance (Clin Cancer Res; 21 (17), 2015). In 2015, the drug resistance analysis on 15 patients with AZD9291 was first reported in Nature Medicine, 21, 560-562, 2015, wherein the third mutation obtained, i.e. EGFR C797S mutation, was one of the main mechanisms leading to drug resistance of Osimertinib, accounting for about 40%. At the same time, the drug resistance of AZD9291 was also reported in several conferences, and among them, 2015 WCLC, Oxnard GR reported drug resistance analysis of 67 patients, of which C797S accounted for about 22%; 2017 ASCO, Piotrowska also reported 23 cases, and C797S also accounted for about 22%; and 2017 ASCO, Zhou Caicun et al reported the analysis of drug resistance mechanisms in 99 patients, of which C797S accounted for about 22%. Therefore, it is of great study significance to overcome the resistance of AZD9291 to C797S mutation and provide patients a safer and more effective fourth-generation EGFR C797S / T790M inhibitor. In 2016, "Nature, 534, 129-132, 2016" reported compound EAI045 capable of overcoming the drug resistance of Osimertinib to C797S. EAI045 belongs to an allosteric inhibitor that shows better tumor inhibition effect in the mouse in vivo pharmacodynamic model with L858R / T790M / C797S mutations when combined with EGFR monoclonal antibody such as cetuximab; but this compound failed to enter clinical studies. In 2017, Nature Communications, 8:14768, 2017 reported that Brigatinib (AP26113) in combination with EGFR monoclonal antibody (such as cetuximab) can overcome the drug resistance of the third-generation targeting drug Osimertinib caused by C797S mutation. It was shown that both the combination of Brigatinib with panitumumab or cetuximab exhibits good antitumor efficacy from the results in the PC9 (EGFR-C797S / T790M / del19) mouse pharmacodynamic model. [Image disponible dans le document PDF, Image available in the PDF document] Brigatinib WO2012051587A1 discloses Comparative Example 1, but failes to provide any data on its effect. [Image disponible dans le document PDF, Image available in the PDF document] Comparative Example 1 SUMMARY OF THE INVENTION The present application provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, [Image disponible dans le document PDF, Image available in the PDF document] , wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, C<com:Sub>5-7< / com:Sub> cycloalkenyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkenyl and <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>; [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] and the structural unit is not selected from: <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>2-6< / com:Sub> alkenyloxy and C<com:Sub>3-6< / com:Sub> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R3<annotation encoding="application / x-tex">R_3< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, <com:Math><semantics>−OC(=O)NH2<annotation encoding="application / x-tex">-OC(=O)NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)NHR<annotation encoding="application / x-tex">-OC(=O)NHR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)NRR<annotation encoding="application / x-tex">-OC(=O)NRR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRC(=O)OR<annotation encoding="application / x-tex">-NRC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OR<annotation encoding="application / x-tex">-NHC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OH<annotation encoding="application / x-tex">-NHC(=O)OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)nNRaRb<annotation encoding="application / x-tex">-O(CH_2)_nNR_aR_b< / annotation>< / semantics>< / com:Math>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl and 5- or 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and 5- or 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2, 3 or 4; R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, C<com:Sub>1-5< / com:Sub> alkyl and C<com:Sub>1-5< / com:Sub> heteroalkyl, wherein said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring is optionally substituted with 1, 2 or 3 R groups; each R<com:Sub>6< / com:Sub> is independently selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, =O and <com:Math><semantics>=S<annotation encoding="application / x-tex">=S< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R7<annotation encoding="application / x-tex">R_7< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R8<annotation encoding="application / x-tex">R_8< / annotation>< / semantics>< / com:Math> are each independently selected from H or <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, <com:Math><semantics>CF3<annotation encoding="application / x-tex">CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>CHF2<annotation encoding="application / x-tex">CHF_2< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>CH2F<annotation encoding="application / x-tex">CH_2F< / annotation>< / semantics>< / com:Math>; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S−<annotation encoding="application / x-tex">-S-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)O−<annotation encoding="application / x-tex">-C(=O)O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)−<annotation encoding="application / x-tex">-C(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=S)−<annotation encoding="application / x-tex">-C(=S)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)−<annotation encoding="application / x-tex">-S(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2−<annotation encoding="application / x-tex">-S(=O)_2-< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(R)C(=O)N(R)−<annotation encoding="application / x-tex">-N(R)C(=O)N(R)-< / annotation>< / semantics>< / com:Math>; in any one of the cases as described above, the number of the heteroatom or heteroatom group is each independently selected from 1, 2 or 3. In some embodiments of the present application, the above R is selected from F, Cl, Br, I, CN, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl and C<com:Sub>1-3< / com:Sub> heteroalkyl, C<com:Sub>2-5< / com:Sub> alkenyloxy, and C<com:Sub>4-6< / com:Sub> cycloalkyloxy, wherein said C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> heteroalkyl, C<com:Sub>2-5< / com:Sub> alkenyloxy and C<com:Sub>4-6< / com:Sub> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups, and R is as defined in the present application. In some embodiments of the present application, the above R<com:Sub>1< / com:Sub> is selected from H, F, Cl, Br, I, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CHO, [Image disponible dans le document PDF, Image available in the PDF document] ≫<com:Sup>O< / com:Sup>, and , wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, [Image disponible dans le document PDF, Image available in the PDF document] CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>O, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CHO, <com:Math><semantics>∘<annotation encoding="application / x-tex">^{\circ}< / annotation>< / semantics>< / com:Math> and are optionally substituted with 1, 2 or 3 R groups, and R is as defined in the present application. In some embodiments of the present application, the above R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl, and 3- to 12-membered heterocycloalkyl, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R groups, and R is as defined in the present application. In some embodiments of the present application, the above R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, [Image disponible dans le document PDF, Image available in the PDF document] • OH, NH<com:Sub>2< / com:Sub>, NO<com:Sub>2< / com:Sub>, -NHR, -N(R)<com:Sub>2< / com:Sub>, and R is as defined in the present application. In some embodiments of the present application, the above R<com:Sub>2< / com:Sub> is selected from H, F, Cl, Br, CN, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above R<com:Sub>6< / com:Sub> is selected from H, F, Cl, Br, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, =S and =O. In some embodiments of the present application, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl, and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with R<com:Sub>6< / com:Sub>, and R<com:Sub>6< / com:Sub> is as defined in the present application. [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the structural unit is selected [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> are optionally substituted with 1, 2 or 3 R groups, and R is as defined in the present application. In some embodiments of the present application, the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently [Image disponible dans le document PDF, Image available in the PDF document] selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above R<com:Sub>3< / com:Sub> is selected from , [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above R<com:Sub>3< / com:Sub> is selected from H, F, Cl, Br, CH<com:Sub>3< / com:Sub>, [Image disponible dans le document PDF, Image available in the PDF document] 5 In some embodiments of the present application, the above R<com:Sub>5< / com:Sub> is selected from H, F, Cl, Br, I, CN, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above R<com:Sub>5< / com:Sub> is selected from H, Cl, Br, CN, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the structural unit <com:Math><semantics>N∼<annotation encoding="application / x-tex">\stackrel{\sim}{N}< / annotation>< / semantics>< / com:Math> is 15 is selected [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or CH<com:Sub>3< / com:Sub>. In some embodiments of the present application, the above R is selected from F, Cl, Br, I, CN, [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , and other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>1< / com:Sub> is selected from H, halogen, C<com:Sub>1-3< / com:Sub> alkyl and <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−5<annotation encoding="application / x-tex">C_{2-5}< / annotation>< / semantics>< / com:Math> alkenyloxy, and <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> heteroalkyl, C<com:Sub>2-5< / com:Sub> alkenyloxy and C<com:Sub>4-6< / com:Sub> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups, and R and other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>1< / com:Sub> is selected from H, F, Cl, Br, I, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CHO, [Image disponible dans le document PDF, Image available in the PDF document] SO, and , wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CHO, or and are optionally substituted with 1, 2 or 3 R groups, and R and other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl, and 3- to 12-membered heterocycloalkyl, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R groups, and R and other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, [Image disponible dans le document PDF, Image available in the PDF document] other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>2< / com:Sub> is selected from H, F, Cl, Br, CN, [Image disponible dans le document PDF, Image available in the PDF document] are as defined above. In some embodiments of the present application, the above R<com:Sub>6< / com:Sub> is selected from H, F, Cl, Br, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, =S and =O, and other variables are as defined above. In some embodiments of the present application, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl, and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math> and other variables are as defined above. [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above structural unit [Image disponible dans le document PDF, Image available in the PDF document] , N and and other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> are optionally substituted with 1, 2 or 3 R groups, and R and other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, <com:Math><semantics>N=N<annotation encoding="application / x-tex">N = N< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>N=N<annotation encoding="application / x-tex">N = N< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>N=N<annotation encoding="application / x-tex">N = N< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>N=N<annotation encoding="application / x-tex">N = N< / annotation>< / semantics>< / com:Math> and other variables are as defined above. [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above R<com:Sub>3< / com:Sub> is selected from , [Image disponible dans le document PDF, Image available in the PDF document] , and other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>3< / com:Sub> is selected from H, F, Cl, Br, CH<com:Sub>3< / com:Sub>, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above R<com:Sub>5< / com:Sub> is selected from H, F, Cl, Br, I, CN, [Image disponible dans le document PDF, Image available in the PDF document] 1, 2 or 3 R groups, and R and other variables are as defined above. In some embodiments of the present application, the above R<com:Sub>5< / com:Sub> is selected from H, Cl, Br, CN, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, the above structural unit <com:Math><semantics>R5<annotation encoding="application / x-tex">R_5< / annotation>< / semantics>< / com:Math> is [Image disponible dans le document PDF, Image available in the PDF document] variables are as defined above. In some embodiments of the present application, the above R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or CH<com:Sub>3< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, the above compound or the pharmaceutically acceptable salt thereof is selected from [Image disponible dans le document PDF, Image available in the PDF document] n , , , , , 5 wherein, R<com:Sub>1< / com:Sub>, R<com:Sub>2< / com:Sub>, R<com:Sub>3< / com:Sub>, R<com:Sub>4< / com:Sub>, R<com:Sub>5< / com:Sub>, R<com:Sub>6< / com:Sub>, R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are as defined above. In some embodiments of the present application, the above compound or the pharmaceutically acceptable salt thereof is selected from [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (V-1) (V-2) , , [Image disponible dans le document PDF, Image available in the PDF document] (V-3) , 5 wherein R<com:Sub>1< / com:Sub>, R<com:Sub>3< / com:Sub>, R<com:Sub>4< / com:Sub>, R<com:Sub>5< / com:Sub>, R<com:Sub>7< / com:Sub>, R<com:Sub>8< / com:Sub>, R and R' are as defined above. The present application provides a compound represented by formula (I') or a pharmaceutically acceptable salt thereof, [Image disponible dans le document PDF, Image available in the PDF document] (I') wherein, <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>2-6< / com:Sub> alkenyloxy, and C<com:Sub>3-6< / com:Sub> cycloalkyloxy group are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R3<annotation encoding="application / x-tex">R_3< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, <com:Math><semantics>−OC(=O)NH2<annotation encoding="application / x-tex">-OC(=O)NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)NHR<annotation encoding="application / x-tex">-OC(=O)NHR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(R)2<annotation encoding="application / x-tex">-OC(=O)N(R)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRC(=O)OR<annotation encoding="application / x-tex">-NRC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OR<annotation encoding="application / x-tex">-NHC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OH<annotation encoding="application / x-tex">-NHC(=O)OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)nNRaRb<annotation encoding="application / x-tex">-O(CH_2)_nNR_aR_b< / annotation>< / semantics>< / com:Math>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2, 3 or 4; <com:Math><semantics>Ra<annotation encoding="application / x-tex">R_a< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R_b< / annotation>< / semantics>< / com:Math> are each independently selected from H, <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl, wherein said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively, R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S and O, wherein the 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O is optionally substituted with 1, 2 or 3 R groups; [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>R9<annotation encoding="application / x-tex">R_9< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R10<annotation encoding="application / x-tex">R_{10}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A, and the structural unit is not [Image disponible dans le document PDF, Image available in the PDF document] selected from: , or alternatively <com:Math><semantics>R10<annotation encoding="application / x-tex">R_{10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A; or alternatively <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R12<annotation encoding="application / x-tex">R_{12}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A; ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl and <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math> is selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, =O and =S; R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or C<com:Sub>1-6< / com:Sub> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein said 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, <com:Math><semantics>CF3<annotation encoding="application / x-tex">CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>CHF2<annotation encoding="application / x-tex">CHF_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>CH2F<annotation encoding="application / x-tex">CH_2F< / annotation>< / semantics>< / com:Math>; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, and 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, N, -NH-, -O-, -S-, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)-, -S (=O)<com:Sub>2< / com:Sub>- or <com:Math><semantics>−N(R)C(=O)N(R)<annotation encoding="application / x-tex">-N(R)C(=O)N(R)< / annotation>< / semantics>< / com:Math>-; in any one of the cases as described above, the number of the heteroatom or heteroatom group is independently selected from 1, 2 or 3. In some embodiments of the present application, the above compound represented by formula (I') or the pharmaceutically acceptable salt thereof is selected from formula (I), [Image disponible dans le document PDF, Image available in the PDF document] (I) wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl and <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>; [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] and the structural unit is not selected from: <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R3<annotation encoding="application / x-tex">R_3< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy or <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, <com:Math><semantics>−OC(=O)NH2<annotation encoding="application / x-tex">-OC(=O)NH_2< / annotation>< / semantics>< / com:Math>, -OC(=O)NHR, -OC(=O)NRR, -NRC(=O)OR, -NHC(=O)OR, -NHC(=O)OH, -O(CH<com:Sub>2< / com:Sub>)<com:Sub>n< / com:Sub>NR<com:Sub>a< / com:Sub>R<com:Sub>b< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2 and 3; R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, C<com:Sub>1-5< / com:Sub> alkyl and C<com:Sub>1-5< / com:Sub> heteroalkyl, wherein said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring is optionally substituted with 1, 2 or 3 R groups; each R<com:Sub>6< / com:Sub> is independently selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, =O and <com:Math><semantics>=S<annotation encoding="application / x-tex">=S< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R7<annotation encoding="application / x-tex">R_7< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R8<annotation encoding="application / x-tex">R_8< / annotation>< / semantics>< / com:Math> are each independently selected from H or <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CF<com:Sub>3< / com:Sub>, CF<com:Sub>2< / com:Sub>H and CFH<com:Sub>2< / com:Sub>; "hetero" represents a heteroatom or a hetero atom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S−<annotation encoding="application / x-tex">-S-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)O−<annotation encoding="application / x-tex">-C(=O)O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)−<annotation encoding="application / x-tex">-C(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=S)−<annotation encoding="application / x-tex">-C(=S)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)−<annotation encoding="application / x-tex">-S(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2−<annotation encoding="application / x-tex">-S(=O)_2-< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−N(R)C(=O)N(R)−<annotation encoding="application / x-tex">-N(R)C(=O)N(R)-< / annotation>< / semantics>< / com:Math>; in any one of the cases as described above, the number of the heteroatom or heteroatom group is each independently selected from 1, 2 or 3. In some embodiments of the present application, the compound represented by the above formula (I') or the pharmaceutically acceptable salt thereof is selected from formula (I<com:Sub>a< / com:Sub>), [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(Ia)<annotation encoding="application / x-tex">(I_a)< / annotation>< / semantics>< / com:Math> wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl and <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R3<annotation encoding="application / x-tex">R_3< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, <com:Math><semantics>−OC(=O)NH2<annotation encoding="application / x-tex">-OC(=O)NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)NHR<annotation encoding="application / x-tex">-OC(=O)NHR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(R)2<annotation encoding="application / x-tex">-OC(=O)N(R)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRC(=O)OR<annotation encoding="application / x-tex">-NRC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OR<annotation encoding="application / x-tex">-NHC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OH<annotation encoding="application / x-tex">-NHC(=O)OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)nNRaRb<annotation encoding="application / x-tex">-O(CH_2)_nNR_aR_b< / annotation>< / semantics>< / com:Math>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2, 3 or 4; R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, C<com:Sub>1-5< / com:Sub> alkyl and C<com:Sub>1-5< / com:Sub> heteroalkyl, wherein said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O is optionally substituted with 1, 2 or 3 R groups; R<com:Sub>6< / com:Sub> is selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, =O and =S; <com:Math><semantics>R7<annotation encoding="application / x-tex">R_7< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R8<annotation encoding="application / x-tex">R_8< / annotation>< / semantics>< / com:Math> are each independently selected from H or <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkenyl, <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkynyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, <com:Math><semantics>CF3<annotation encoding="application / x-tex">CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>CHF2<annotation encoding="application / x-tex">CHF_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>CH2F<annotation encoding="application / x-tex">CH_2F< / annotation>< / semantics>< / com:Math>; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S−<annotation encoding="application / x-tex">-S-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)O−<annotation encoding="application / x-tex">-C(=O)O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)−<annotation encoding="application / x-tex">-C(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=S)−<annotation encoding="application / x-tex">-C(=S)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)−<annotation encoding="application / x-tex">-S(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2−<annotation encoding="application / x-tex">-S(=O)_2-< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(R)C(=O)N(R)−<annotation encoding="application / x-tex">-N(R)C(=O)N(R)-< / annotation>< / semantics>< / com:Math>; in any one of the cases as described above, the number of the heteroatom or heteroatom group is each independently selected from 1, 2 or 3. In some embodiments of the present application, the compound represented by the above formula (I') or the pharmaceutically acceptable salt thereof is selected from formula (I<com:Sub>b< / com:Sub>), [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(Ib)<annotation encoding="application / x-tex">(I_b)< / annotation>< / semantics>< / com:Math> wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl and <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C3−14<annotation encoding="application / x-tex">C_{3-14}< / annotation>< / semantics>< / com:Math> cycloalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R3<annotation encoding="application / x-tex">R_3< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, <com:Math><semantics>−OC(=O)NH2<annotation encoding="application / x-tex">-OC(=O)NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)NHR<annotation encoding="application / x-tex">-OC(=O)NHR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(R)2<annotation encoding="application / x-tex">-OC(=O)N(R)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRC(=O)OR<annotation encoding="application / x-tex">-NRC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OR<annotation encoding="application / x-tex">-NHC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OH<annotation encoding="application / x-tex">-NHC(=O)OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)nNRaRb<annotation encoding="application / x-tex">-O(CH_2)_nNR_aR_b< / annotation>< / semantics>< / com:Math>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2, 3 or 4; R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, C<com:Sub>1-5< / com:Sub> alkyl and C<com:Sub>1-5< / com:Sub> heteroalkyl, wherein said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O is optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math> is selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, =O and =S; <com:Math><semantics>R7<annotation encoding="application / x-tex">R_7< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R8<annotation encoding="application / x-tex">R_8< / annotation>< / semantics>< / com:Math> are each independently selected from H or <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkenyl, <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkynyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkenyl, <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkynyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, <com:Math><semantics>CF3<annotation encoding="application / x-tex">CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>CHF2<annotation encoding="application / x-tex">CHF_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>CH2F<annotation encoding="application / x-tex">CH_2F< / annotation>< / semantics>< / com:Math>; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S−<annotation encoding="application / x-tex">-S-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)O−<annotation encoding="application / x-tex">-C(=O)O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)−<annotation encoding="application / x-tex">-C(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=S)−<annotation encoding="application / x-tex">-C(=S)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)−<annotation encoding="application / x-tex">-S(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2−<annotation encoding="application / x-tex">-S(=O)_2-< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(R)C(=O)N(R)−<annotation encoding="application / x-tex">-N(R)C(=O)N(R)-< / annotation>< / semantics>< / com:Math>; in any one of the cases as described above, the number of the heteroatom or heteroatom group is each independently selected from 1, 2 or 3. In some embodiments of the present application, in formula (I'), the above R is selected from F, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in the formula (I'), the above <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−5<annotation encoding="application / x-tex">C_{2-5}< / annotation>< / semantics>< / com:Math> alkenyloxy or <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> heteroalkyl, C<com:Sub>2-5< / com:Sub> alkenyloxy and C<com:Sub>4-6< / com:Sub> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups. In some embodiments of the present application, in the formula (I'), the above <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, F, Cl, Br, I, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>O, [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(CH3)2CHO<annotation encoding="application / x-tex">(CH_3)_2CHO< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>O<annotation encoding="application / x-tex">O< / annotation>< / semantics>< / com:Math> and , wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, [Image disponible dans le document PDF, Image available in the PDF document] CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CHO, <com:Math><semantics>∼<annotation encoding="application / x-tex">\sim< / annotation>< / semantics>< / com:Math> and are optionally substituted with 1, 2 or 3 R groups. In some embodiments of the present application, in formula (I'), the above R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R groups. In some embodiments of the present application, in formula (I'), R<com:Sub>2< / com:Sub> is selected from H, halogen, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above R<com:Sub>2< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above R<com:Sub>6< / com:Sub> is selected from H, F, Cl, Br, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, =S and =O. In some embodiments of the present application, in formula (I'), when R<com:Sub>9< / com:Sub> and R<com:Sub>10< / com:Sub> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>. In some embodiments of the present application, in formula (I'), when R<com:Sub>9< / com:Sub> and R<com:Sub>10< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from , [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), when <com:Math><semantics>R10<annotation encoding="application / x-tex">R_{10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>. In some embodiments of the present application, in formula (I'), when R<com:Sub>10< / com:Sub> and R<com:Sub>11< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), when <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R12<annotation encoding="application / x-tex">R_{12}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>. In some embodiments of the present application, in formula (I'), when <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R12<annotation encoding="application / x-tex">R_{12}< / annotation>< / semantics>< / com:Math> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> are optionally substituted with 1, 2 or 3 R groups. In some embodiments of the present application, in formula (I'), the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each [Image disponible dans le document PDF, Image available in the PDF document] independently selected from H, and <com:Math><semantics>−S(=O)2CH3<annotation encoding="application / x-tex">-S(=O)_2CH_3< / annotation>< / semantics>< / com:Math>. In some embodiments of the present application, in formula (I'), the above R<com:Sub>3< / com:Sub> is selected from [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above R<com:Sub>3< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] F, Cl, Br, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub> and . In some embodiments of the present application, in formula (I'), the above R<com:Sub>5< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above R<com:Sub>5< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above structural unit [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] is selected from In some embodiments of the present application, in formula (I'), the above R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or CH<com:Sub>3< / com:Sub>. In some embodiments of the present application, in formula (I'), the above R is selected from F, 1 Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>N, < N \, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above R<com:Sub>1< / com:Sub> is selected from H, halogen, <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−5<annotation encoding="application / x-tex">C_{2-5}< / annotation>< / semantics>< / com:Math> alkenyloxy and <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−3<annotation encoding="application / x-tex">C_{1-3}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−5<annotation encoding="application / x-tex">C_{2-5}< / annotation>< / semantics>< / com:Math> alkenyloxy, and <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, F, Cl, Br, I, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(CH3)2CHO<annotation encoding="application / x-tex">(CH_3)_2CHO< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>∼<annotation encoding="application / x-tex">\sim< / annotation>< / semantics>< / com:Math> and , wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, [Image disponible dans le document PDF, Image available in the PDF document] CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CHO, O, and are optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above R<com:Sub>2< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] halogen, CN, OH, NH<com:Sub>2< / com:Sub>, NO<com:Sub>2< / com:Sub>, -NHR, -N(R)<com:Sub>2< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above R<com:Sub>2< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] 15 and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math> is selected from H, F, Cl, Br, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, =S and =O, and other variables are as defined above. In some embodiments of the present application, in formula (I'), when R<com:Sub>9< / com:Sub> and R<com:Sub>10< / com:Sub> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are so optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>, and other variables are as defined above. In some embodiments of the present application, in formula (I'), when R<com:Sub>9< / com:Sub> and R<com:Sub>10< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] and ı , and other variables are as defined above. In some embodiments of the present application, in formula (I'), when <com:Math><semantics>R10<annotation encoding="application / x-tex">R_{10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>, and other variables are as defined above. In some embodiments of the present application, in formula (I'), when R<com:Sub>10< / com:Sub> and R<com:Sub>11< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from , [Image disponible dans le document PDF, Image available in the PDF document] - - In some embodiments of the present application, in formula (I'), when <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R12<annotation encoding="application / x-tex">R_{12}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, imidazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>, and other variables are as defined above. In some embodiments of the present application, in formula (I'), when <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R12<annotation encoding="application / x-tex">R_{12}< / annotation>< / semantics>< / com:Math> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from , [Image disponible dans le document PDF, Image available in the PDF document] variables are as defined above. In some embodiments of the present application, in formula (I'), the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> are optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above R<com:Sub>3< / com:Sub> is selected from [Image disponible dans le document PDF, Image available in the PDF document] , and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above R<com:Sub>3< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above R<com:Sub>5< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above R<com:Sub>5< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I'), the above structural unit [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] is selected from , and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or CH<com:Sub>3< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, in formula (I'), the above compound or the pharmaceutically acceptable salt thereof is selected from [Image disponible dans le document PDF, Image available in the PDF document] , , , 7 , 5 wherein R<com:Sub>1< / com:Sub>, R<com:Sub>2< / com:Sub>, R<com:Sub>3< / com:Sub>, R<com:Sub>4< / com:Sub>, R<com:Sub>5< / com:Sub>, R<com:Sub>6< / com:Sub>, R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are as defined above. The present application provides a compound represented by formula (I") or a pharmaceutically acceptable salt thereof, [Image disponible dans le document PDF, Image available in the PDF document] (I") wherein, R<com:Sub>1< / com:Sub> is selected from H, halogen, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>2-6< / com:Sub> alkenyloxy and C<com:Sub>3-6< / com:Sub> cycloalkyloxy, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R3<annotation encoding="application / x-tex">R_3< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, <com:Math><semantics>−OC(=O)NH2<annotation encoding="application / x-tex">-OC(=O)NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)NHR<annotation encoding="application / x-tex">-OC(=O)NHR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(R)2<annotation encoding="application / x-tex">-OC(=O)N(R)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRC(=O)OR<annotation encoding="application / x-tex">-NRC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OR<annotation encoding="application / x-tex">-NHC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OH<annotation encoding="application / x-tex">-NHC(=O)OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)nNRaRb<annotation encoding="application / x-tex">-O(CH_2)_nNR_aR_b< / annotation>< / semantics>< / com:Math>, C<com:Sub>1-6< / com:Sub> alkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said C<com:Sub>1-6< / com:Sub> alkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2, 3 or 4; R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, C<com:Sub>1-5< / com:Sub> alkyl and C<com:Sub>1-5< / com:Sub> heteroalkyl, wherein said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O is optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R9<annotation encoding="application / x-tex">R_9< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R10<annotation encoding="application / x-tex">R_{10}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A; or alternatively <com:Math><semantics>R10<annotation encoding="application / x-tex">R_{10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A; or alternatively <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R12<annotation encoding="application / x-tex">R_{12}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A; ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl and C<com:Sub>5-7< / com:Sub> cycloalkyl are optionally substituted with R<com:Sub>6< / com:Sub>; <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math> is selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, =O and =S; R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or C<com:Sub>1-6< / com:Sub> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, <com:Math><semantics>CF3<annotation encoding="application / x-tex">CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>CHF2<annotation encoding="application / x-tex">CHF_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>CH2F<annotation encoding="application / x-tex">CH_2F< / annotation>< / semantics>< / com:Math>; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O−,−S−,−C(=O)O−,−C(=O)−,−C(=S)−,−S(=O)−,−S(=O)2−<annotation encoding="application / x-tex">-O_{-}, -S_{-}, -C(=O)O_{-}, -C(=O)_{-}, -C(=S)_{-}, -S(=O)_{-}, -S(=O)_{2}_{-}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(R)C(=O)N(R)−<annotation encoding="application / x-tex">-N(R)C(=O)N(R)_{-}< / annotation>< / semantics>< / com:Math>; in any one of the cases as described above, the number of the heteroatom or heteroatom group is each independently selected from 1, 2 or 3. In some embodiments of the present application, the compound represented by the above formula (I") or the pharmaceutically acceptable salt thereof is selected from formula (I), [Image disponible dans le document PDF, Image available in the PDF document] (I) wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl and <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>; [Image disponible dans le document PDF, Image available in the PDF document] and the structural unit , R<com:Sub>1< / com:Sub> is selected from H, halogen, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>2-6< / com:Sub> alkenyloxy and C<com:Sub>3-6< / com:Sub> cycloalkyloxy, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>2-6< / com:Sub> alkenyloxy and C<com:Sub>3-6< / com:Sub> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>3< / com:Sub> is selected from H, halogen, C<com:Sub>1-6< / com:Sub> alkoxy, C<com:Sub>2-6< / com:Sub> alkenyloxy, C<com:Sub>3-6< / com:Sub> cycloalkyloxy, -OC(=O)NH<com:Sub>2< / com:Sub>, <com:Math><semantics>−OC(=O)NHR<annotation encoding="application / x-tex">-OC(=O)NHR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)NRR<annotation encoding="application / x-tex">-OC(=O)NRR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRC(=O)OR<annotation encoding="application / x-tex">-NRC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OR<annotation encoding="application / x-tex">-NHC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OH<annotation encoding="application / x-tex">-NHC(=O)OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)nNRaRb<annotation encoding="application / x-tex">-O(CH_2)_nNR_aR_b< / annotation>< / semantics>< / com:Math>, C<com:Sub>1-6< / com:Sub> alkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said C<com:Sub>1-6< / com:Sub> alkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2 or 3; R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, C<com:Sub>1-5< / com:Sub> alkyl and C<com:Sub>1-5< / com:Sub> heteroalkyl, wherein said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring is optionally substituted with 1, 2 or 3 R groups; each R<com:Sub>6< / com:Sub> is independently selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, =O and <com:Math><semantics>=S<annotation encoding="application / x-tex">=S< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R7<annotation encoding="application / x-tex">R_7< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R8<annotation encoding="application / x-tex">R_8< / annotation>< / semantics>< / com:Math> are each independently selected from H or <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein the C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, <com:Math><semantics>C4−6<annotation encoding="application / x-tex">C_{4-6}< / annotation>< / semantics>< / com:Math> cycloalkynyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CF<com:Sub>3< / com:Sub>, CF<com:Sub>2< / com:Sub>H and CFH<com:Sub>2< / com:Sub>; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S−<annotation encoding="application / x-tex">-S-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)O−<annotation encoding="application / x-tex">-C(=O)O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)−<annotation encoding="application / x-tex">-C(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=S)−<annotation encoding="application / x-tex">-C(=S)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)−<annotation encoding="application / x-tex">-S(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2−<annotation encoding="application / x-tex">-S(=O)_2-< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(R)C(=O)N(R)−<annotation encoding="application / x-tex">-N(R)C(=O)N(R)-< / annotation>< / semantics>< / com:Math>; in any one of the cases as described above, the number of the heteroatom or heteroatom group is independently selected from 1, 2 or 3. In some embodiments of the present application, the compound represented by the above formula (I") or the pharmaceutically acceptable salt thereof is selected from formula (I<com:Sub>a< / com:Sub>), [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(Ia)<annotation encoding="application / x-tex">(I_a)< / annotation>< / semantics>< / com:Math> wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl and C<com:Sub>5-7< / com:Sub> cycloalkyl are optionally substituted with R<com:Sub>6< / com:Sub>; <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>2-6< / com:Sub> alkenyloxy, and C<com:Sub>3-6< / com:Sub> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, pheny and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R3<annotation encoding="application / x-tex">R_3< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, <com:Math><semantics>−OC(=O)NH2<annotation encoding="application / x-tex">-OC(=O)NH_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)NHR<annotation encoding="application / x-tex">-OC(=O)NHR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(R)2<annotation encoding="application / x-tex">-OC(=O)N(R)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRC(=O)OR<annotation encoding="application / x-tex">-NRC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OR<annotation encoding="application / x-tex">-NHC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OH<annotation encoding="application / x-tex">-NHC(=O)OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)nNRaRb<annotation encoding="application / x-tex">-O(CH_2)_nNR_aR_b< / annotation>< / semantics>< / com:Math>, C<com:Sub>1-6< / com:Sub> alkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said C<com:Sub>1-6< / com:Sub> alkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2, 3 or 4; <com:Math><semantics>Ra<annotation encoding="application / x-tex">R_a< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Rb<annotation encoding="application / x-tex">R_b< / annotation>< / semantics>< / com:Math> are each independently selected from H, <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl, and said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively, R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O is optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math> is selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, =O and =S; <com:Math><semantics>R7<annotation encoding="application / x-tex">R_7< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R8<annotation encoding="application / x-tex">R_8< / annotation>< / semantics>< / com:Math> are each independently selected from H or <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein said 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, <com:Math><semantics>CF3<annotation encoding="application / x-tex">CF_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>CHF2<annotation encoding="application / x-tex">CHF_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>CH2F<annotation encoding="application / x-tex">CH_2F< / annotation>< / semantics>< / com:Math>; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S−<annotation encoding="application / x-tex">-S-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)O−<annotation encoding="application / x-tex">-C(=O)O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)−<annotation encoding="application / x-tex">-C(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=S)−<annotation encoding="application / x-tex">-C(=S)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)−<annotation encoding="application / x-tex">-S(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2−<annotation encoding="application / x-tex">-S(=O)_2-< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(R)C(=O)N(R)−<annotation encoding="application / x-tex">-N(R)C(=O)N(R)-< / annotation>< / semantics>< / com:Math>; in any one of the cases as described above, the number of the heteroatom or heteroatom group is each independently selected from 1, 2 or 3. In some embodiments of the present application, the compound represented by the above formula (I") or the pharmaceutically acceptable salt thereof is selected from formula (I<com:Sub>b< / com:Sub>), [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(Ib)<annotation encoding="application / x-tex">(I_b)< / annotation>< / semantics>< / com:Math> wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, and C<com:Sub>5-7< / com:Sub> cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl and <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>; R<com:Sub>1< / com:Sub> is selected from H, halogen, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>2-6< / com:Sub> alkenyloxy and C<com:Sub>3-6< / com:Sub> cycloalkyloxy, wherein said <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C2−6<annotation encoding="application / x-tex">C_{2-6}< / annotation>< / semantics>< / com:Math> alkenyloxy, and <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; R<com:Sub>3< / com:Sub> is selected from H, halogen, C<com:Sub>1-6< / com:Sub> alkoxy, C<com:Sub>2-6< / com:Sub> alkenyloxy, C<com:Sub>3-6< / com:Sub> cycloalkyloxy, -OC(=O)NH<com:Sub>2< / com:Sub>, <com:Math><semantics>−OC(=O)NHR<annotation encoding="application / x-tex">-OC(=O)NHR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(=O)N(R)2<annotation encoding="application / x-tex">-OC(=O)N(R)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NRC(=O)OR<annotation encoding="application / x-tex">-NRC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OR<annotation encoding="application / x-tex">-NHC(=O)OR< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NHC(=O)OH<annotation encoding="application / x-tex">-NHC(=O)OH< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−O(CH2)nNRaRb<annotation encoding="application / x-tex">-O(CH_2)_nNR_aR_b< / annotation>< / semantics>< / com:Math>, C<com:Sub>1-6< / com:Sub> alkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, wherein said C<com:Sub>1-6< / com:Sub> alkyl and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2, 3 or 4; R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, C<com:Sub>1-5< / com:Sub> alkyl and C<com:Sub>1-5< / com:Sub> heteroalkyl, wherein said <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> alkyl and <com:Math><semantics>C1−5<annotation encoding="application / x-tex">C_{1-5}< / annotation>< / semantics>< / com:Math> heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring; R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are each independently selected from H, halogen, CN, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring containing 1, 2 or 3 atoms independently selected from N, S or O is optionally substituted with 1, 2 or 3 R groups; R<com:Sub>6< / com:Sub> is selected from H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, =O and =S; R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or C<com:Sub>1-6< / com:Sub> alkyl; or alternatively R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are bonded together to form a 5- to 6-membered heterocyclic ring, wherein the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, wherein said C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CF<com:Sub>3< / com:Sub>, CHF<com:Sub>2< / com:Sub>, or CH<com:Sub>2< / com:Sub>F; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-5< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>N<annotation encoding="application / x-tex">N< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O−<annotation encoding="application / x-tex">-O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S−<annotation encoding="application / x-tex">-S-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)O−<annotation encoding="application / x-tex">-C(=O)O-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=O)−<annotation encoding="application / x-tex">-C(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(=S)−<annotation encoding="application / x-tex">-C(=S)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)−<annotation encoding="application / x-tex">-S(=O)-< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)2−<annotation encoding="application / x-tex">-S(=O)_2-< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>−N(R)C(=O)N(R)−<annotation encoding="application / x-tex">-N(R)C(=O)N(R)-< / annotation>< / semantics>< / com:Math>; in any one of the cases as described above, the number of the heteroatom or heteroatom group is each independently selected from 1, 2 or 3. In some embodiments of the present application, in formula (I"), the above R is selected from F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>N, \( \sigma^{\mathbb{N}} \). [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I"), the above R<com:Sub>1< / com:Sub> is selected from H, halogen, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> heteroalkyl, C<com:Sub>2-5< / com:Sub> alkenyloxy, and C<com:Sub>4-6< / com:Sub> cycloalkyloxy, wherein said C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> heteroalkyl, C<com:Sub>2-5< / com:Sub> alkenyloxy and C<com:Sub>4-6< / com:Sub> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups. In some embodiments of the present application, in formula (I"), the above R<com:Sub>1< / com:Sub> is selected from H, F, Cl, Br, I, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>O, [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(CH3)2CHO<annotation encoding="application / x-tex">(CH_3)_2CHO< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>○<annotation encoding="application / x-tex">\bigcirc< / annotation>< / semantics>< / com:Math> and In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R groups. In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] halogen, CN, OH, NH<com:Sub>2< / com:Sub>, NO<com:Sub>2< / com:Sub>, -NHR, -N(R)<com:Sub>2< / com:Sub>, In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] 1 F, Cl, Br, CN, OH, NH<com:Sub>2< / com:Sub>, NO<com:Sub>2< / com:Sub>, ) [Image disponible dans le document PDF, Image available in the PDF document] . In some embodiments of the present application, in formula (I"), the above R<com:Sub>6< / com:Sub> is selected from H, F, Cl, Br, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, =S and =O. In some embodiments of the present application, in formula (I"), when R<com:Sub>9< / com:Sub> and R<com:Sub>10< / com:Sub> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with R<com:Sub>6< / com:Sub>. In some embodiments of the present application, in formula (I"), when R<com:Sub>9< / com:Sub> and R<com:Sub>10< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from , [Image disponible dans le document PDF, Image available in the PDF document] . [Image disponible dans le document PDF, Image available in the PDF document] • In some embodiments of the present application, in formula (I"), when <com:Math><semantics>R10<annotation encoding="application / x-tex">R_{10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with R<com:Sub>6< / com:Sub>. In some embodiments of the present application, in formula (I"), when <com:Math><semantics>R10<annotation encoding="application / x-tex">R_{10}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the above structural unit is selected from [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I"), when <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R12<annotation encoding="application / x-tex">R_{12}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with R<com:Sub>6< / com:Sub>. In some embodiments of the present application, in formula (I"), when R<com:Sub>11< / com:Sub> and R<com:Sub>12< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from , [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I"), the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and <com:Math><semantics>−S(=O)2CH3<annotation encoding="application / x-tex">-S(=O)_2CH_3< / annotation>< / semantics>< / com:Math> are optionally substituted with 1, 2 or 3 R groups. In some embodiments of the present application, in formula (I"), the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each [Image disponible dans le document PDF, Image available in the PDF document] independently selected from H, In some embodiments of the present application, in formula (I"), the above R<com:Sub>3< / com:Sub> is selected from [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I"), the above R<com:Sub>3< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] F, Cl, Br, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub> and In some embodiments of the present application, in formula (I"), the above R<com:Sub>5< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I"), the above R<com:Sub>5< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I"), the above structural unit [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] is selected from In some embodiments of the present application, in formula (I"), the above R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or CH<com:Sub>3< / com:Sub>. In some embodiments of the present application, in formula (I"), the above R is selected from F, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>1< / com:Sub> is selected from H, halogen, C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> heteroalkyl, C<com:Sub>2-5< / com:Sub> alkenyloxy, and C<com:Sub>4-6< / com:Sub> cycloalkyloxy, wherein said C<com:Sub>1-3< / com:Sub> alkyl, C<com:Sub>1-3< / com:Sub> heteroalkyl, C<com:Sub>2-5< / com:Sub> alkenyloxy, and C<com:Sub>4-6< / com:Sub> cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from H, F, Cl, Br, I, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>O, [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(CH3)2CHO<annotation encoding="application / x-tex">(CH_3)_2CHO< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>○<annotation encoding="application / x-tex">\bigcirc< / annotation>< / semantics>< / com:Math> and , and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from H, halogen, CN, OH, NO<com:Sub>2< / com:Sub>, NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl, wherein said NH<com:Sub>2< / com:Sub>, C<com:Sub>3-12< / com:Sub> cycloalkyl and 3- to 12-membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] halogen, CN, OH, NH<com:Sub>2< / com:Sub>, NO<com:Sub>2< / com:Sub>, -NHR, -N(R)<com:Sub>2< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] 1 5 F, Cl, Br, CN, OH, NH<com:Sub>2< / com:Sub>, NO<com:Sub>2< / com:Sub>, [Image disponible dans le document PDF, Image available in the PDF document] and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>6< / com:Sub> is selected from H, F, Cl, Br, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, CH<com:Sub>3< / com:Sub>O, =S and =O, and other variables are as defined above. In some embodiments of the present application, in formula (I"), when R<com:Sub>9< / com:Sub> and R<com:Sub>10< / com:Sub> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), when R<com:Sub>9< / com:Sub> and R<com:Sub>10< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from • Ν and , and other variables are as defined above. In some embodiments of the present application, in formula (I"), when R<com:Sub>10< / com:Sub> and R<com:Sub>11< / com:Sub> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), when R<com:Sub>10< / com:Sub> and R<com:Sub>11< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form ring A, the structural unit is selected from , [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , and other variables are as defined above. In some embodiments of the present application, in formula (I"), when <com:Math><semantics>R11<annotation encoding="application / x-tex">R_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R12<annotation encoding="application / x-tex">R_{12}< / annotation>< / semantics>< / com:Math> are bonded together to form ring A, ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl and pyrrolyl are optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), when R<com:Sub>11< / com:Sub> and R<com:Sub>12< / com:Sub> are bonded [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] together to form a ring A, the above structural unit is selected from ) [Image disponible dans le document PDF, Image available in the PDF document] variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each independently selected from H, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, and -S(=O)<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub> are optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>a< / com:Sub> and R<com:Sub>b< / com:Sub> are each [Image disponible dans le document PDF, Image available in the PDF document] independently selected from H, and <com:Math><semantics>−S(=O)2CH3<annotation encoding="application / x-tex">-S(=O)_2CH_3< / annotation>< / semantics>< / com:Math>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>3< / com:Sub> is selected from [Image disponible dans le document PDF, Image available in the PDF document] , and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>3< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] F, Cl, Br, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub> and , and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>5< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] F, Cl, Br, I, CN, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, NH. and , wherein said CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, 0~ <com:Math><semantics>NH<annotation encoding="application / x-tex">NH< / annotation>< / semantics>< / com:Math> are optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>5< / com:Sub> is selected from H, [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I"), the above structural unit [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] is selected from , and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from H or CH<com:Sub>3< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above compound or the pharmaceutically acceptable salt thereof is selected from [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (II) (III) , , [Image disponible dans le document PDF, Image available in the PDF document] , • wherein R<com:Sub>1< / com:Sub>, R<com:Sub>2< / com:Sub>, R<com:Sub>3< / com:Sub>, R<com:Sub>4< / com:Sub>, R<com:Sub>5< / com:Sub>, R<com:Sub>6< / com:Sub>, R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are as defined above. The present application provides a compound represented by formula (I"') or a pharmaceutically acceptable salt thereof, [Image disponible dans le document PDF, Image available in the PDF document] (I"") wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, or <com:Math><semantics>C5−7<annotation encoding="application / x-tex">C_{5-7}< / annotation>< / semantics>< / com:Math> cycloalkyl, which is optionally substituted with <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math>; [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] and the structural unit is not selected from R<com:Sub>1< / com:Sub> is selected from H or halogen, or selected from C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> alkenyloxy or <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkoxy group, which is optionally substituted with 1, 2 or 3 R groups; R<com:Sub>2< / com:Sub> is selected from: H, halogen, CN, OH, or NO<com:Sub>2< / com:Sub>, or selected from NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-14< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, phenyl, or 3- to 14-membered heterocyclic group, which is optionally substituted with 1, 2 or 3 R groups; <com:Math><semantics>R3<annotation encoding="application / x-tex">R_3< / annotation>< / semantics>< / com:Math> is selected from H, halogen, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> alkenyloxy or <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyloxy, <com:Math><semantics>−OC(=O)NH2<annotation encoding="application / x-tex">-OC(=O)NH_2< / annotation>< / semantics>< / com:Math>, -OC(=O)NHR, -OC(=O)NRR, -NRC(=O)OR, -NHC(=O)OR, or -NHC(=O)OH, or selected from C<com:Sub>1-6< / com:Sub> alkyl, or 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms, which is optionally substituted with 1, 2 or 3 R groups; R<com:Sub>4< / com:Sub> is selected from: H or NH<com:Sub>2< / com:Sub>; R<com:Sub>5< / com:Sub> is selected from H or halogen, or selected from NH<com:Sub>2< / com:Sub>, C<com:Sub>1-4< / com:Sub> alkyl, C<com:Sub>1-4< / com:Sub> heteroalkyl, phenyl or 5- to 6-membered heterocyclic group, which is optionally substituted with 1, 2 or 3 R groups; or alternatively R<com:Sub>4< / com:Sub> and R<com:Sub>5< / com:Sub> are bonded together to form a 5- to 6-membered ring containing 1, 2 or 3 heteroatoms independently selected from N, S or O, which is optionally substituted with 1, 2 or 3 R groups; R<com:Sub>6< / com:Sub> is independently selected from: H, halogen, CN, OH, NH<com:Sub>2< / com:Sub>, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, =O, or <com:Math><semantics>=S;<annotation encoding="application / x-tex">=S;< / annotation>< / semantics>< / com:Math> <com:Math><semantics>R7<annotation encoding="application / x-tex">R_7< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R8<annotation encoding="application / x-tex">R_8< / annotation>< / semantics>< / com:Math> are each independently selected from H, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl; R is selected from halogen, CN, OH, or NH<com:Sub>2< / com:Sub>, or selected from C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>2-6< / com:Sub> alkenyl, C<com:Sub>2-6< / com:Sub> alkynyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkenyl, C<com:Sub>4-6< / com:Sub> cycloalkynyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, phenyl or 5- to 6-membered heteroaryl, which is optionally substituted with 1, 2 or 3 R' groups; R' is selected from: H, F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, or <com:Math><semantics>CH3O;<annotation encoding="application / x-tex">CH_3O;< / annotation>< / semantics>< / com:Math> "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, C<com:Sub>1-6< / com:Sub> heteroalkyl, 3- to 14-membered heterocyclic group, C<com:Sub>1-4< / com:Sub> heteroalkyl, C<com:Sub>1-6< / com:Sub> heteroalkyl, C<com:Sub>3-6< / com:Sub> heterocycloalkyl, or 5- to 6-membered heteroaryl is independently selected from: <com:Math><semantics>−C(=O)N(R)<annotation encoding="application / x-tex">-C(=O)N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(R)<annotation encoding="application / x-tex">-N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NR)<annotation encoding="application / x-tex">-C(=NR)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−(R)C=N<annotation encoding="application / x-tex">-(R)C=N< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(R)<annotation encoding="application / x-tex">-S(=O)_2N(R)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)N(R)<annotation encoding="application / x-tex">-S(=O)N(R)< / annotation>< / semantics>< / com:Math>-, N, <com:Math><semantics>−NH<annotation encoding="application / x-tex">-NH< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−O<annotation encoding="application / x-tex">-O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S<annotation encoding="application / x-tex">-S< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>2-, or <com:Math><semantics>−N(R)C(=O)N(R)<annotation encoding="application / x-tex">-N(R)C(=O)N(R)< / annotation>< / semantics>< / com:Math>-; in any one of the cases as described above, the number of the heteroatom or heteroatom group is each independently selected from 1, 2 or 3. In some embodiments of the present application, in formula (I"), the above R is selected from: F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, or CH<com:Sub>3< / com:Sub>O. In some embodiments of the present application, in formula (I"'), the above R<com:Sub>1< / com:Sub> is selected from: H, F, Cl, Br, I, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, or <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl. In some embodiments of the present application, in formula (I'''), the above <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from: O- - In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from: H, halogen, CN, OH, or NO<com:Sub>2< / com:Sub>, or selected from C<com:Sub>3-14< / com:Sub> cycloalkyl, or 3- to 14-membered heterocyclic group, which is optionally substituted with 1, 2 or 3 R groups. In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from: H, [Image disponible dans le document PDF, Image available in the PDF document] halogen, CN, OH, NH<com:Sub>2< / com:Sub>, NO<com:Sub>2< / com:Sub>, -NHR, -NRR, In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from: [Image disponible dans le document PDF, Image available in the PDF document] 1 In some embodiments of the present application, in formula (I"'), the above ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, or cyclopentanonyl, which is optionally substituted with R<com:Sub>6< / com:Sub>. In some embodiments of the present application, in formula (I"), the above structural unit [Image disponible dans le document PDF, Image available in the PDF document] Ν is selected from: O , [Image disponible dans le document PDF, Image available in the PDF document] In some embodiments of the present application, in formula (I"'), the above R<com:Sub>3< / com:Sub> is selected from: H, Cl, and CH<com:Sub>3< / com:Sub>. In some embodiments of the present application, in formula (I"), the above R<com:Sub>4< / com:Sub> is selected from: Η. In some embodiments of the present application, in formula (I"), the above R<com:Sub>5< / com:Sub> is selected from: H, or Cl. In some embodiments of the present application, in formula (I"), the above R<com:Sub>6< / com:Sub> is selected from: H, or CH<com:Sub>3< / com:Sub>. In some embodiments of the present application, in formula (I"), the above R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are each independently selected from: CH<com:Sub>3< / com:Sub>. In some embodiments of the present application, in formula (I"), the above R is selected from F, Cl, Br, I, CN, OH, NH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>, CH<com:Sub>3< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>, (CH<com:Sub>3< / com:Sub>)<com:Sub>2< / com:Sub>CH, or CH<com:Sub>3< / com:Sub>O, and other variables are as defined above. In some embodiments of the present application, in formula (I'''), the above <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from: H, F, Cl, Br, I, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, or <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> heteroalkyl, and other variables are as defined above. In some embodiments of the present application, in formula (I'''), the above <com:Math><semantics>R1<annotation encoding="application / x-tex">R_1< / annotation>< / semantics>< / com:Math> is selected from: , and the other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from: H, halogen, CN, OH, or NO<com:Sub>2< / com:Sub>, or selected from C<com:Sub>3-14< / com:Sub> cycloalkyl or 3- to 14-membered heterocyclic group optionally substituted with 1, 2 or 3 R groups, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from: H, [Image disponible dans le document PDF, Image available in the PDF document] halogen, CN, OH, NH<com:Sub>2< / com:Sub>, NO<com:Sub>2< / com:Sub>, -NHR, -NRR, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>2< / com:Sub> is selected from: [Image disponible dans le document PDF, Image available in the PDF document] , and other variables are as defined above. In some embodiments of the present application, in formula (I"'), the above ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, or cyclopentanonyl, which is optionally substituted with R<com:Sub>6< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above structural unit [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] is selected from: <com:Math><semantics>∼<annotation encoding="application / x-tex">\sim< / annotation>< / semantics>< / com:Math> <com:Math><semantics>N⊙<annotation encoding="application / x-tex">N_{\odot}< / annotation>< / semantics>< / com:Math> [Image disponible dans le document PDF, Image available in the PDF document] , or , and other variables as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>3< / com:Sub> is selected from H, Cl, or CH<com:Sub>3< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above R<com:Sub>4< / com:Sub> is selected from H, and other variables are as defined above. In some embodiments of the present application, in formula (I'''), the above R<com:Sub>5< / com:Sub> is selected from H, or Cl, and other variables are as defined above. In some embodiments of the present application, in Formula (I'''), the above <com:Math><semantics>R6<annotation encoding="application / x-tex">R_6< / annotation>< / semantics>< / com:Math> is selected from H, or CH<com:Sub>3< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, in formula (I"'), the above R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> above are each independently selected from CH<com:Sub>3< / com:Sub>, and other variables are as defined above. In some embodiments of the present application, in formula (I"), the above compound or the pharmaceutically acceptable salt thereof is selected from [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (II) (III) [Image disponible dans le document PDF, Image available in the PDF document] , [Image disponible dans le document PDF, Image available in the PDF document] , (IV) (V) , , [Image disponible dans le document PDF, Image available in the PDF document] (IV) , wherein R<com:Sub>1< / com:Sub>, R<com:Sub>2< / com:Sub>, R<com:Sub>3< / com:Sub>, R<com:Sub>4< / com:Sub>, R<com:Sub>5< / com:Sub>, R<com:Sub>6< / com:Sub>, R<com:Sub>7< / com:Sub> and R<com:Sub>8< / com:Sub> are as defined above. The present application also provides the following compounds or the pharmaceutically 5 acceptable salts thereof [Image disponible dans le document PDF, Image available in the PDF document] - - [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] . [Image disponible dans le document PDF, Image available in the PDF document] - • . . [Image disponible dans le document PDF, Image available in the PDF document] • . [Image disponible dans le document PDF, Image available in the PDF document] . [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] The present application also provides a pharmaceutical composition comprising a therapeutically effective amount of the above compound or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present application also provides use of the above compound or the pharmaceutically acceptable salt thereof, or the above pharmaceutical composition in the manufacture of a medicament for treating cancer. The present application also provides use of the above compound or the pharmaceutically acceptable salt thereof, or the above pharmaceutical composition for treating cancer. The application also provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of the above compound, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition thereof. The present application also provides use of the above compound or the pharmaceutically acceptable salt thereof in combination with EGFR monoclonal antibody in the manufacture of a medicament for treating cancer. The application also provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of the above compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof, and an EGFR monoclonal antibody. In some embodiments of the present application, the above EGFR monoclonal antibody is cetuximab. The application also provides a method for treating cancer, comprising administering to a subject a therapeutically effective amount of the above compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof, and a MEK inhibitor. In some embodiments of the present application, the cancer is lung cancer. In the present application, still other embodiments are derived from any combination of the above variables. Technical effect The compounds of the present application show excellent antiproliferative activity on EGFR Ba / F3 cell with three mutations (Δ19del / T790M / C797S) and phosphorylation activity in the model of EGFR Ba / F3 cell with three mutations (Δ19del / T790M / C797S). The compound of the present application exhibits unexpected inhibitory activity compared to Comparative Example 1. Definitions and Introductions Unless otherwise stated, the following terms and phrases as used herein are intended to have the following meanings. A particular term or phrase should not be considered to be indefinite or unclear in absence of a specific definition, but should be interpreted as its ordinary meanings. When a trade name appears herein, it is intended to refer to the corresponding commodity or active ingredient thereof. The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable salt" refers to a salt of the compound of the present application, which is prepared from a compound having aspecific substituent found in the present application and a relatively non-toxic acid or base. When the compound of the present application contains a relatively acidic functional group, the base addition salt thereof can be obtained by contacting such compound in neutral form with a sufficient amount of base in a pure solution or a suitable inert solvent. When the compound of the present application contains a relatively basic functional group, the acid addition salt thereof can be obtained by contacting such compound in neutral form with a sufficient amount of acid in a pure solution or a suitable inert solvent. Examples of the pharmaceutically acceptable acid addition salt include inorganic acid salts, organic acid salts, ammonium salts, and salts of organic acids such as glucuronic acid. Certain specific compounds of the application contain basic and acidic functional groups, which can be converted to either base or acid addition salt. The pharmaceutically acceptable salts of the present application can be synthesized from the parent compound containing an acidic moiety or a basic moiety by conventional chemical methods. Generally, such salt is prepared by reacting the free acid or base form of the compound with a stoichiometric amount of an appropriate base or acid in water or an organic solvent or a mixture thereof. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. In addition to the salt form, the compound provided herein also exists in prodrug form. The prodrug of the compound described herein is the compound that readily undergoes chemical change under physiological condition, to be converted into the compound of the application. Furthermore, the prodrug can be converted to the compounds of the application by a chemical or biochemical method in an in vivo environment. Certain compounds of the application can exist in an unsolvated from or a solvated form, including a hydrated form. Generally, the solvated form is equivalent to the unsolvated form, and both are encompassed within the scope of the application. The compounds of the present application may exist in specific geometric or stereoisomeric forms. All such compounds envisaged by the present invention include cis and trans isomers, (-)- and (+)-enantiomer pairs, <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- and <com:Math><semantics>(S)<annotation encoding="application / x-tex">(S)< / annotation>< / semantics>< / com:Math>-enantiomers, diastereoisomers, <com:Math><semantics>(D)<annotation encoding="application / x-tex">(D)< / annotation>< / semantics>< / com:Math>-isomers, (L)-isomers, and racemic mixtures thereof, and other mixtures thereof, such as enantiomers or diastereomers enriched mixtures, all of which fall within the scope of the present application. Other asymmetric carbon atoms may be present in the substituents such as alkyl. All these isomers and their mixtures are included within the scope of the present application. Unless otherwise indicated, the term "enantiomer" or "optical isomer" refers to stereoisomers that are mirror images of each other. Unless otherwise indicated, the term "cis-trans isomer" or "geometric isomer" is caused by the inability of a double bond or a single bond of carbon atoms on the ring to freely rotate. Unless otherwise indicated, the term "diastereomer" refers to stereoisomers in which the molecules have two or more chiral centers and are not mirror images of each other. Unless otherwise indicated, "<com:Math><semantics>(D)<annotation encoding="application / x-tex">(D)< / annotation>< / semantics>< / com:Math>" or "<com:Math><semantics>(+)<annotation encoding="application / x-tex">(+)< / annotation>< / semantics>< / com:Math>" stands for dextrorotation, "<com:Math><semantics>(L)<annotation encoding="application / x-tex">(L)< / annotation>< / semantics>< / com:Math>" or "<com:Math><semantics>(−)<annotation encoding="application / x-tex">(-)< / annotation>< / semantics>< / com:Math>" stands for levorotation, "<com:Math><semantics>(DL)<annotation encoding="application / x-tex">(DL)< / annotation>< / semantics>< / com:Math>" or "<com:Math><semantics>(±)<annotation encoding="application / x-tex">(\pm)< / annotation>< / semantics>< / com:Math>" stands for racemization. Unless otherwise indicated, the absolute configuration of a stereogenic center is represented by a wedge solid bond ( ) and a wedge dashed bond ( ), and the relative configuration of a stereogenic center is represented by a straight solid bond (") and a straight dashed bond (""). A wave line ( •••• ) represents a wedge solid bond ( •••• ) or a wedgedashed bond ( •••• ), or represents a straight solid bond ( ) and a straight dashed bond ( ""). The compounds of the present application may be present in particular. Unless otherwise indicated, the terms "tautomer" or "tautomeric form" refer to the fact that the different functional isomers are in dynamic equilibrium at room temperature and can be rapidly converted into each other. If tautomers are possible (such as in solution), the chemical equilibrium of the tautomers can be achieved. For example, proton tautomers (also known as prototropic tautomers) include interconversions by proton transfer, such as keto-enol isomerization and imine-enamine isomerization. The valence tautomer includes the mutual transformation of some bonding electrons. A specific example of keto-enol tautomerization is the interconversion between two tautomers of pentane-2,4-dione and 4-hydroxypent-3-en-2-one. Unless otherwise indicated, the term "enriched in one isomer", "isomer enriched", "enriched in one enantiomer" or " enantiomer enriched" refers to that the content of one of the isomers or enantiomers is less than 100%, and the content of the isomer or enantiomer is 60% or more, or 70% or more, or 80% or more, or 90% or more, or 95% or more, or 96% or more, or 97% or more, or 98% or more, or 99% or more, or 99.5% or more, or 99.6% or more, or 99.7% or more, or 99.8% or more, or 99.9% or more. Unless otherwise indicated, the term "excess of isomer" or "excess of enantiomer" refers to the difference between the relative percentages of the two isomers or enantiomers. For example, wherein, the content of one of the isomers or enantiomers is 90%, and the other one is 10%, then the excess of isomer or enantiomeric (ee value) is 80%. The optically active <com:Math><semantics>(R)<annotation encoding="application / x-tex">(R)< / annotation>< / semantics>< / com:Math>- and <com:Math><semantics>(S)<annotation encoding="application / x-tex">(S)< / annotation>< / semantics>< / com:Math>-isomers as well as the <com:Math><semantics>D<annotation encoding="application / x-tex">D< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>L<annotation encoding="application / x-tex">L< / annotation>< / semantics>< / com:Math> isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If an enantiomer of a certain compound of the present application is desired, it may be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the ancillary group is cleaved to provide the pure desired enantiomers. Alternatively, when a molecule contains a basic functional group (such as an amino) or an acidic functional group (such as a carboxyl), it forms a salt of diastereomer with a suitable optically active acid or base, and then a diastereomer resolution is performed by a conventional method well known in the art, followed by recovering to give the pure enantiomer. In addition, the separation of the enantiomers and diastereomers is generally accomplished by the use of chromatography adopting a chiral stationary phase, and optionally in combination with chemical derivatization method (e.g., formation of carbamates from amines). The compounds of the present application may contain non-natural proportions of atomic isotopes on one or more atoms which constitute the compound. For example, the compound may be labeled with a radioisotope, such as tritium (<com:Sup>3< / com:Sup>H), iodine-125 (125I) or C-14 (14C). Any isotopic composition transformations of the compound of the application, whether are radioactive or not, are included within the scope of the present application. The term "pharmaceutically acceptable carrier" refers to any formulation or carrier medium capable of delivering an effective amount of an active substance of the present application, without interfering with the biological activity of the active substance and having no toxic side effects on the host or patient. Representative carriers include water, oils, vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspensions, tackifiers, transdermal enhancers etc. Their formulations are well known to those skilled in the cosmetic field or topical drug arts. The term "excipient" generally refers to the carrier, diluent and / or medium which is required to formulate an effective pharmaceutical composition. The term "effective amount" or "therapeutically effective amount" with respect to drugs or pharmacologically active agents refers to a sufficient amount of a drug or agent that is non-toxic but can achieve the desired effect. For the oral dosage form in the present application, the "effective amount" of one active substance in a composition means the amount required to achieve the desired effect when used in combination with another active substance in the composition. The determination of the effective amount will vary with each individual, depending on the age and general condition of the subject, as well as the specific active substance. The appropriate effective amount in each case can be determined by the skilled in the art according to a routine experiment. The term "active ingredient", "therapeutic agent", "active substance" or "active agent" refers to a chemical entity that can effectively treat a target disorder, disease or condition. "Optional" or "optionally" means that the subsequently described event or situation may, but is not necessarily to, occur, and the description includes instances in which the event or situation occurs and instances in which the event or situation does not occur. The term "substituted" means that any one or more of the hydrogen atoms on a specific atom are substituted by a substituent (which may include heavy hydrogen and variants of hydrogen), as long as the valence state of the specific atom is normal and the substituted compound is stable. When the substituent is oxygen (i.e., =O), it means that two hydrogen atoms are substituted. Oxygen substitution does not occur on an aromatic group. The term "optionally substituted" means that it may or may not be substituted, unless otherwise specified; the type and number of the substituent may be arbitrary as long as being chemically achievable. When any variable (e.g., R) appears more than once in composition or structure of a compound, its definition in each case is independent. Thus, for example, if a group is substituted by 0-2 R, this group may be optionally substituted by at most two R, and R in each case has an independent option. Furthermore, the combination of substituents and / or variants thereof is permissible only if such combination results in stable compounds. When the number of a linking group is 0, such as -(CRR)<com:Sub>0< / com:Sub>-, it means that the linking group is a single bond. When one of the variables is selected from a single bond, it means that the two groups linke by the single bond are connected directly. For example, when L in A-L-Z represents a single bond, the structure of A-L-Z is actually A-Z. When a substituent is vacant, it means that the substituent does not exist. For example, when X is vacant in A-X, the structure is actually A. When a substituent can be bond to more than one atom on a ring, the substituent may be bonded to any atom on the ring. For example, the [Image disponible dans le document PDF, Image available in the PDF document] structural unit means that the substituent R may occur at any position on cyclohexyl or cyclohexadiene. When the listed substituents are not indicated by which atom is attached to the substituted group, such a substituent may be bonded through any of its atoms, for example, pyridyl as a substituent may be bonded to the substituted group through any one of carbon atoms on the pyridine ring. When the enumerative linking group does not indicate the direction for linking, the direction for linking is arbitrary. For example, the linking [Image disponible dans le document PDF, Image available in the PDF document] group L in is -M-W-, then the -M-W- can link ring A and ring B to form [Image disponible dans le document PDF, Image available in the PDF document] in the direction same as left-to-right reading order, and form [Image disponible dans le document PDF, Image available in the PDF document] in the direction contrary to left-to-right reading order. Combinations of the linking groups, substituents and / or variants thereof are permissible only if such combinations result in stable compounds. Unless otherwise specified, the term "hetero" refers to a heteroatom or a heteroatomic group (i.e., an atomic group containing a heteroatom), including the atom other than carbon (C) and hydrogen (H), and the atomic group containing these heteroatoms, including, for example, oxygen (O), nitrogen (N), sulfur (S), silicon (Si), germanium (Ge), aluminum (Al), boron (B), -O-, -S-, =O, =S, <com:Math><semantics>−C(=O)O<annotation encoding="application / x-tex">-C(=O)O< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=O)<annotation encoding="application / x-tex">-C(=O)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=S)<annotation encoding="application / x-tex">-C(=S)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(=O)<annotation encoding="application / x-tex">-S(=O)< / annotation>< / semantics>< / com:Math><com:Sub>2< / com:Sub>-, and <com:Math><semantics>−C(=O)N(H)<annotation encoding="application / x-tex">-C(=O)N(H)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−N(H)<annotation encoding="application / x-tex">-N(H)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−C(=NH)<annotation encoding="application / x-tex">-C(=NH)< / annotation>< / semantics>< / com:Math>-, <com:Math><semantics>−S(=O)2N(H)<annotation encoding="application / x-tex">-S(=O)_2N(H)< / annotation>< / semantics>< / com:Math>- or <com:Math><semantics>−S(=O)N(H)<annotation encoding="application / x-tex">-S(=O)N(H)< / annotation>< / semantics>< / com:Math>-, each of which is optionally substituted. Unless otherwise specified, "ring" refers to a substituted or unsubstituted cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, heterocycloalkynyl, aryl or heteroaryl. The so-called ring includes a single ring, a bicyclic ring, a spiral ring, a fused ring or a bridged ring. The number of the atom on the ring is usually defined as the membernumber of the ring. For example, "5- to 7-membered ring" means that 5 to 7 atoms are arranged on a ring. Unless otherwise specified, the ring optionally contains 1 to 3 heteroatoms. Thus, a "5- to 7-membered ring" includes, for example, phenyl, pyridine, and piperidinyl; on the other hand, the term "5- to 7-membered heterocycloalkyl ring" includes pyridyl and piperidinyl, but excluding phenyl. The term "ring" also includes a ring system containing at least one ring, wherein each "ring" independently meets the above definition. Unless otherwise specified, the term "heterocycle" or "heterocyclyl" refers to a stable monocyclic, bicyclic or tricyclic ring containing a heteroatom or heteroatom group, which can be saturated, partially unsaturated or unsaturated (aromatic), and can contain carbon atoms and 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S, wherein any of the above heterocycles can be fused to a benzene ring to form a bicyclic ring. Nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)<com:Sub>p< / com:Sub>, p is 1 or 2). Nitrogen atom can be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as already defined herein). The heterocycle can be attached to the pendant groups of any heteroatom or carbon atom to form a stable structure. If the resulting compound is stable, the heterocycles described herein can undergo substitution at a carbon or nitrogen position. Nitrogen atom on the heterocycle is optionally quaternized. In a preferred embodiment, when the total number of S and O atom in the heterocycle is more than 1, the heteroatom is not adjacent to each other. In another preferred embodiment, the total number of S and O atom of the heterocycle is not more than 1. The term "aromatic heterocyclic group" or "heteroaryl" as used herein refers to a stable 5-, 6-, or 7-membered monocyclic or bicyclic, or 7-, 8-, 9- or 10-membered bicyclic heterocyclic aromatic ring, which contains carbon atoms and 1, 2, 3 or 4 ring heteroatoms independently selected from N, O and S. Nitrogen atom can be substituted or unsubstituted (i.e., N or NR, wherein R is H or other substituents as already defined herein). Nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)<com:Sub>p< / com:Sub>, p is 1 or 2). It is worth noting that the total number of S and O atom of an aromatic heterocycle is not more than 1. The bridged ring is also included in the definition of the heterocycle. A bridged ring is formed when one or more atoms (i.e., C, O, N, or S) link two non-adjacent carbon or nitrogen atoms. A preferred bridged ring includes, but not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and one carbon-nitrogen group. It is worth noting that a bridge always converts a monocyclicring to a tricyclic ring. In the bridged ring, the substituent on the ring may also be present on the bridge. Examples of the heterocyclic compound include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiolfuranyl, benzothiolphenyl, benzoxazolyl, benzoxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbazolinyl, chromanyl, chromene, cinnolinyl decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuranyl, furyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolenyl, indolizinly, indolyl, 3H-indolyl, isobenzofuranyl, isoindolyl, isoindolinyll, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, hydroxyindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, benzoxanthinyl, phenoloxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidinonyl, 4-piperidinonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, isothiazolylthiophenyl, thienoxazolyl, thienothiazolyl, thienoimidazolyl, thienyl, triazinyl, <com:Math><semantics>1H−1,2,3<annotation encoding="application / x-tex">1H-1,2,3< / annotation>< / semantics>< / com:Math>-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl, 4H-1,2,4-triazolyl and xanthenyl. Also included are fused ring and spiro ring compounds. Unless otherwise specified, the term "hydrocarbyl" or its hyponyms (e.g., alkyl, alkenyl, alkynyl, aryl, etc.), by itself or as part of another substituent, refers to a straight, branched chain or cyclic hydrocarbon radical or a combination thereof, thay can be fully saturated (such as alkyl), mono- or polyunsaturated (e.g., alkenyl, alkynyl, and aryl), can be mono- or polysubstituted, and can be monovalent (e.g., methyl), divalent (e.g., methylene) or multivalent (e.g., methenyl), can include a divalent or multivalent group, have a specified number of carbon atom (e.g., <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>-<com:Math><semantics>C12<annotation encoding="application / x-tex">C_{12}< / annotation>< / semantics>< / com:Math> represents 1 to 12 carbon atoms, <com:Math><semantics>C1−12<annotation encoding="application / x-tex">C_{1-12}< / annotation>< / semantics>< / com:Math> is selected from <com:Math><semantics>C1<annotation encoding="application / x-tex">C_1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C2<annotation encoding="application / x-tex">C_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C3<annotation encoding="application / x-tex">C_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C4<annotation encoding="application / x-tex">C_4< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C5<annotation encoding="application / x-tex">C_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C6<annotation encoding="application / x-tex">C_6< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C7<annotation encoding="application / x-tex">C_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C8<annotation encoding="application / x-tex">C_8< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C9<annotation encoding="application / x-tex">C_9< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C10<annotation encoding="application / x-tex">C_{10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C11<annotation encoding="application / x-tex">C_{11}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>C12<annotation encoding="application / x-tex">C_{12}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C3−12<annotation encoding="application / x-tex">C_{3-12}< / annotation>< / semantics>< / com:Math> is selected from C<com:Sub>3< / com:Sub>, C<com:Sub>4< / com:Sub>, C<com:Sub>5< / com:Sub>, C<com:Sub>6< / com:Sub>, C<com:Sub>7< / com:Sub>, C<com:Sub>8< / com:Sub>, C<com:Sub>9< / com:Sub>, C<com:Sub>10< / com:Sub>, C<com:Sub>11< / com:Sub> and C<com:Sub>12< / com:Sub>). "Hydrocarbyl" includes, but is not limited to, aliphatic hydrocarbyl and aromatic hydrocarbyl, the aliphatic hydrocarbyl includes linear and cyclic hydrocarbyl, specifically includes but not limited to alkyl, alkenyl, and alkynyl, and the aromatic hydrocarbyl includes, but is not limited to, 6- to 12-membered aromatic hydrocarbyl, such as phenyl, naphthyl and the like. In some embodiments, the term "hydrocarbyl" means a straight or branched group or a combination thereof, which can be fully saturated, mono- or polyunsaturated, and can include a divalent or multivalent radical. Examples of the saturated hydrocarbyl radical include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, isobutyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, and the homolog or isomer of n-pentyl, n-hexyl, n-heptyl, n-octyl and the like. The unsaturated hydrocarbyl group has one or more double or triple bonds, and examples thereof include, but are not limited to, vinyl, 2-propenyl, butenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and more higher homologs and isomers. Unless otherwise specified, the term "heterohydrocarbyl" or its hyponyms (such as heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl, etc.), by itself or in combination with another term, denotes a stable straight, branched or cyclic hydrocarbon radical or any combination thereof, which havs a specified number of carbon atoms and at least one heteroatom. Unless otherwise specified, the term "heteroalkyl" by itself or in combination with another term denotes a stable straight chain, branched hydrocarbon radical or a combination thereof, having a specified number of carbon atoms and at least one heteroatom. In a specific embodiment, a heteroatom is selected from B, O, N, and S, wherein nitrogen and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. The heteroatom or heteroatom group can be located at any internal position of a heterohydrocarbyl, including the position where the hydrocarbyl is attached to the rest part of the molecule. But the terms "alkoxy", "alkylamino" and "alkylthio" (or thioalkoxy) belong to customary expression, which denotes an alkyl which are attached to the rest part of the molecule via an oxygen atom, an amino or a sulfur atom respectively. Examples of "heteroalkyl" include, but are not limited to, -OCH<com:Sub>3< / com:Sub>, -OCH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, -OCH<com:Sub>2< / com:Sub>CH<com:Sub>2< / com:Sub>CH<com:Sub>3< / com:Sub>, <com:Math><semantics>−OCH(CH3)2<annotation encoding="application / x-tex">-OCH(CH_3)_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>−N(CH3)2<annotation encoding="application / x-tex">-N(CH_3)_2< / annotation>< / semantics>< / com:Math>, -CH<com:Sub>2< / com:Sub>-CH<com:Sub>2< / com:Sub>-O-CH<com:Sub>3< / com:Sub>, -CH<com:Sub>2< / com:Sub>-CH<com:Sub>2< / com:Sub>-NH-CH<com:Sub>3< / com:Sub>, <com:Math><semantics>−CH2−CH2−N(CH3)−CH3<annotation encoding="application / x-tex">-CH_2-CH_2-N(CH_3)-CH_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2−S−CH2−CH3<annotation encoding="application / x-tex">-CH_2-S-CH_2-CH_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−CH2−CH2<annotation encoding="application / x-tex">-CH_2-CH_2< / annotation>< / semantics>< / com:Math> <com:Math><semantics>−S(O)−CH3<annotation encoding="application / x-tex">-S(O)-CH_3< / annotation>< / semantics>< / com:Math> <com:Math><semantics>−S(O)2−CH3<annotation encoding="application / x-tex">-S(O)_2-CH_3< / annotation>< / semantics>< / com:Math> -CH<com:Sub>2< / com:Sub>-CH<com:Sub>2< / com:Sub>-S(O)<com:Sub>2< / com:Sub>-CH<com:Sub>3< / com:Sub>, -CH=CH-O-CH<com:Sub>3< / com:Sub>, -CH<com:Sub>2< / com:Sub>-CH=N-OCH<com:Sub>3< / com:Sub> and -CH=CH-N(CH<com:Sub>3< / com:Sub>)-CH<com:Sub>3< / com:Sub>. Up to two heteroatoms can be continuous, such as -CH<com:Sub>2< / com:Sub>-NH-OCH<com:Sub>3< / com:Sub>. Unless otherwise specified, the term "cyclohydrocarbyl", "heterocyclohydrocarbyl" or its hyponyms (such as aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, cycloalkynyl, heterocycloalkynyl, etc.), by itself or in combination with other terms, represents a cyclized "hydrocarbyl" or "heterohydrocarbyl", respectively. Furthermore, for heterohydrocarbyl or heterocyclohydrocarbyl (e.g., heteroalkyl or heterocycloalkyl), a heteroatom can occupy the position where the heterocyclic ring is attached to the rest part of the molecule. Examples of cyclohydrocarbyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Non-limiting examples of heterocyclic groups include 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl and 2-piperazinyl. Unless otherwise specified, the term "alkyl" refers to a straight or branched saturated hydrocarbon group, which can be mono- (e.g., -CH<com:Sub>2< / com:Sub>F) or poly-substituted (e.g., -CF<com:Sub>3< / com:Sub>), and can be monovalent (e.g., methyl), divalent (e.g., methylene) or multivalent (e.g., methenyl). Examples of alkyl include methyl (Me), ethyl (Et), propyl (such as, n-propyl and isopropyl), butyl (such as n-butyl, isobutyl, s-butyl, t-butyl), pentyl (such as n-pentyl, isopentyl, neopentyl) and the like. Unless otherwise specified, "alkenyl" refers to an alkyl group having one or more carbon-carbon double bonds at any position of the chain, which can be mono-substituted or poly-substituted, and can be monovalent, divalent or multivalent. Examples of alkenyl include vinyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl and the like. The term "alkenyloxy" refers to an alkenyl group which are each attached to the rest part of the molecule through an oxygen atom, examples including, but not limited to, CH<com:Sub>2< / com:Sub>=CH-O-, CH<com:Sub>3< / com:Sub>CH=CH-O-. Unless otherwise specified, "alkynyl" refers to an alkyl group having one or more carbon-carbon triple bonds at any position of the chain, which can be mono-substituted or poly-substituted, and can be monovalent, divalent or multivalent. Examples of alkynyl include ethynyl, propynyl, butynyl, pentynyl and the like. Unless otherwise specified, "cycloalkyl" includes any stable cyclic or polycyclic hydrocarbyl, and any carbon atom is saturated, which can be mono-substituted or poly-substituted, and can be monovalent, divalent or multivalent. Examples of such cycloalkyl include, but are not limited to, cyclopropyl, norbornanyl, [2.2.2]bicyclooctane, [4.4.0]bicyclodecanyl, and the like. However, the term "cycloalkyloxy" refers to the cycloalkyl group which are each attached to the rest part of [Image disponible dans le document PDF, Image available in the PDF document] the molecule through an oxygen atom, examples including, but not limited to, , [Image disponible dans le document PDF, Image available in the PDF document] Unless otherwise specified, "cycloalkenyl" includes any stable cyclic or polycyclic hydrocarbyl containing one or more unsaturated carbon-carbon double bonds at any position of the ring, which can be mono-substituted or poly-substituted, and an be monovalent, divalent or multivalent. Examples of such cycloalkenyl include, but are not limited to, cyclopentenyl, cyclohexenyl, and the like. Unless otherwise specified, "cycloalkynyl" includes any stable cyclic or polycyclic hydrocarbyl containing one or more carbon-carbon triple bonds at any position of the ring, which can be mono-substituted or poly-substituted, and can be monovalent, divalent or multivalent. Unless otherwise specified, the term "halo" or "halogen", by itself or as part of another substituent, refers to fluorine, chlorine, bromine or iodine atom. Furthermore, the term "haloalkyl" is intended to include both monohaloalkyl and polyhaloalkyl. For example, the term "halo(C<com:Sub>1< / com:Sub>-C<com:Sub>4< / com:Sub>)alkyl" is intended to include, but not limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like. Unless otherwise specified, examples of haloalkyl include, but not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. "Alkoxy" represents any alkyl defined above having a specified number of carbon atoms attached by an oxygen bridge. Unless otherwise specified, C<com:Sub>1-6< / com:Sub> alkoxy includes C<com:Sub>1< / com:Sub>, C<com:Sub>2< / com:Sub>, C<com:Sub>3< / com:Sub>, C<com:Sub>4< / com:Sub>, C<com:Sub>5< / com:Sub> and C<com:Sub>6< / com:Sub> alkoxy. Examples of alkoxy include, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy and S-pentyloxy. Unless otherwise specified, the term "aryl" refers to a polyunsaturated aromatic substituent, can be mono- or poly-substituted, can be monovalent, divalent or polyvalent, can be a single ring or multiple rings (for example, 1 to 3 rings; wherein at least one ring is aromatic), which are fused together or covalently connected. Unless otherwise specified, the term "heteroaryl" refers to an aryl (or ring) containing one to four heteroatoms. In an illustrative example, the heteroatom is selected from B, N, O, and S, wherein nitrogen and sulfur atoms are optionally oxidized, and nitrogen atom is optionally quaternized. A heteroaryl may attach to the rest part of a molecule via a heteroatom. Non-limiting examples of aryl or heteroaryl include phenyl, naphthyl, biphenyl, pyrrolyl, pyrazolyl, imidazolyl, pyrazinyl, oxazolyl, phenyl-oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidinyl, benzothiazolyl, purinyl, benzimidazolyl, indolyl, isoquinolyl, quinoxalinyl, quinolinyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolinyl, 5-isoquinolinyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl and 6-quinolinyl. The substituent of any of the above aryl and heteroaryl ring system is selected from the acceptable substituents described below. Unless otherwise specified, when combined with other terms (such as aryloxy, arylthio, aralkyl), the aryl includes the aryl and heteroaryl rings as defined above. Thus, the term "aralkyl" is intended to include the groups (e.g., benzyl, phenethyl, pyridylmethyl, etc.) where an aryl is attached to an alkyl, including an alkyl where the carbon atom (e.g., methylene) has been replaced by an atom such as oxygen, for example, phenoxymethyl, 2-pyridyloxymethyl 3-(1-naphthyloxy)propyl, and the like. The term "leaving group" refers to a functional group or atom which can be replaced by another functional group or atom through a substitution reaction (for example an affinity substitution reaction). For example, representative leaving groups include triflate; chlorine, bromine and iodine; sulfonate, such as mesylate, tosylate, p-bromobenzenesulfonate, p-toluenesulfonate and the like; acyloxy, such as acetoxy, trifluoroacetoxy and the like. The term "protecting group" includes, but is not limited to, "amino protecting group", "hydroxy protecting group" or "thiol protecting group". The term "amino protecting group" refers to a protecting group suitable for preventing side reactions at the nitrogen position on the amino. Representative amino protecting groups include, but are not limited to, formyl; acyl, such as alkanoyl (e.g., acetyl, trichloroacetyl or trifluoroacetyl); alkoxycarbonyl, such as, tert-butoxycarbonyl (Boc); arylmethoxycarbonyl, such as benzyloxycarbonyl (Cbz) and 9-fluorenylmethyloxycarbonyl (Fmoc); arylmethyl, such as benzyl (Bn), trityl (Tr), 1,1-di-(4'-methoxyphenyl)methyl; silyl, such as trimethylsilyl (TMS) and tert-butyldimethylsilyl (TBS), etc. The term "hydroxy protecting group" refers to a protecting group suitable for use in preventing side reactions of hydroxyl. Representative hydroxy protecting groups include, but are not limited to, alkyl, such as methyl, ethyl and tert-butyl; acyl, such as alkanoyl (e.g., acetyl); arylmethyl, such as benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm) and diphenylmethyl (benzhydryl, DPM); silyl, such as trimethylsilyl (TMS), tert-butyl dimethylsilyl (TBS), etc. The compounds of the present application can be prepared by a variety of synthetic methods well known by those skilled in the art, including the following exemplified embodiments, the embodiments formed by combining them with other chemical synthesis methods, and equivalent alternatives known to those skilled in the art. Preferred embodiments include, but are not limited to the examples of the present invention. The solvents used in the present application are commercially available. The present application employs the following abbreviations: aq represents aqua; eq represents equivalent; CDI represents carbonyldiimidazole; DCM represents dichloromethane; PE represents petroleum ether; DMF represents N,N-dimethylformamide; DMSO represents dimethyl sulfoxide; EtOAc represents ethyl acetate; EtOH represents ethanol; MeOH represents methanol; BOC represents t-butyl carbonyl, which is an amine protecting group; HOAc represents acetic acid; Na(OAc)<com:Sub>3< / com:Sub>BH represents sodium borohydride acetate; THF represents tetrahydrofuran; Boc<com:Sub>2< / com:Sub>O represents di-tert-butyl dicarbonate; TFA represents trifluoroacetic acid; Cu(acac)<com:Sub>2< / com:Sub> represents copper acetylacetonate; DIEA represents diisopropylethylamine; Xantphos represents 9,9-dimethyl-4,5-bisdiphenylphospheno xanthene; Pd(OAc)<com:Sub>2< / com:Sub> represents palladium acetate; Pd(dppf)Cl<com:Sub>2< / com:Sub> represents [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride; K<com:Sub>3< / com:Sub>PO<com:Sub>4< / com:Sub> represents potassium phosphate; K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> represents potassium carbonate; NaHCO<com:Sub>3< / com:Sub> represents sodium hydrogencarbonate; Na<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> represents sodium carbonate; HCl represents hydrogen chloride; Pd / C represents palladium carbon; ICl represents iodine chloride; NaH represents sodium hydride; DMAP represents 4-dimethyl aminopyridine; DIPEA / DIEA represents N,N'-diisopropylethylamine; DPPF represents 1,1'-bis(diphenylphosphino)ferrocene; DCE represents 1,2-dichloroethane; DME represents dimethoxyethane. Compounds are named manually or by ChemDraw® software, and the commercially available compounds use their vendor directory names. DETAILED DESCRIPTION The application is described in detail below with the following examples, but does not mean any adverse limitation to the application. The present application has been specified herein, wherein the particular embodiments of the present application are disclosed. Various variation and modifications will be made to the embodiments of the present application without departing from the spirit and scope of the present application, which would be apparent for the skilled in the art. Example 1 Compound 1A: [Image disponible dans le document PDF, Image available in the PDF document] Under protection of nitrogen gas, 5-bromobenzothiophene (10 g, 46.93 mmol), K<com:Sub>3< / com:Sub>PO<com:Sub>4< / com:Sub> (9.96 g, 46.93 mmol) and Cu(acac)<com:Sub>2< / com:Sub> (644 mg, 1.16 mmol, 0.05 eq.) were dissolved in DMF solution in liquid ammonia (2M, 50 mL). The reaction solution was reacted in a high-pressure reactor at 100 °C for 12 hours. The reaction solution was filtered and the filtrate was concentrated to give a crude product. The crude product was purified by column chromatography to obtain compound 1A. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=7.65<annotation encoding="application / x-tex">\delta = 7.65< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.39 (d, <com:Math><semantics>J=5.3<annotation encoding="application / x-tex">J = 5.3< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.16 (d, <com:Math><semantics>J=5.3<annotation encoding="application / x-tex">J = 5.3< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.11 (s, 1H), 6.79 (dd, <com:Math><semantics>J=1.8,8.5<annotation encoding="application / x-tex">J = 1.8, 8.5< / annotation>< / semantics>< / com:Math> Hz, 1H), 3.67 (br s, 2H). Compound 1B: [Image disponible dans le document PDF, Image available in the PDF document] Compound 1A (3.8 g, 25.47 mmol) and NaHCO<com:Sub>3< / com:Sub> (4.28 g, 50.93 mmol) were dissolved in 50 mL of DCM and then added dropwise with iodine chloride (4.96 g, 30.56 mmol, 1.56 mL), and the reaction solution was reacted at 20 °C for 1 hour. After the reaction was completed, the reaction solution was added with 100 mL of DCM and washed respectively with water and saturated brine. The organic phases were combined, dried and concentrated to give compound 1B. Compound 1C: [Image disponible dans le document PDF, Image available in the PDF document] Compound 1B (0.6 g, 2.18 mmol), dimethylphosphine oxide (364.76 mg, 3.27 mmol), Xantphos (126.19 mg, 218.10 μmol), Pd(OAc)<com:Sub>2< / com:Sub> (48.96 mg, 218.10 μmol), and K<com:Sub>3< / com:Sub>PO<com:Sub>4< / com:Sub> (694.41 mg, 3.27 mmol) were dissolved in 10 mL of DMF and 2 mL of H<com:Sub>2< / com:Sub>O, and the reaction was carried out at 120 °C under the protection of nitrogen gas for 24 hours. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain compound 1C. Compound 1D: [Image disponible dans le document PDF, Image available in the PDF document] Compound 1C (0.3 g, 1.33 mmol) was dissolved in 5 mL of EtOH, and 2,4,5-trichloropyrimidine (488.59 mg, 2.66 mmol, 303.47 μL) and DIEA (688.54 mg, 5.33 mmol, 927.95 µL) were added thereto. The reaction solution was refluxed under the protection of nitrogen gas for 24 hours. After the reaction was completed, the reaction solution was concentrated and purified by column chromatography to obtain compound 1D. Compound 1E: [Image disponible dans le document PDF, Image available in the PDF document] The compounds of 1-chloro-2-fluoro-4-methoxy-5-nitrobenzene and 3-methyl-3,9-diazaspiro[5.5]undecane were dissolved in 30 mL of DMF, and then K<com:Sub>2< / com:Sub>CO<com:Sub>3< / com:Sub> (5.04 g, 36.48 mmol) was added. The reaction was carried out at 60 °C under the protection of nitrogen for 8 hours. After the reaction was completed, the reaction solution was filtered, and the filtrate was concentrated and purified by column chromatography to obtain compound 1E. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=8.05<annotation encoding="application / x-tex">\delta = 8.05< / annotation>< / semantics>< / com:Math> (s, 1H), 6.57 (s, 1H), 3.96 (s, 3H), 3.19-3.11 (m, 4H), 2.42 (m, 4H), 2.31 (s, 3H), 1.71-1.67 (m, 4H), 1.65-1.61 (m, 4H). Compound 1F: [Image disponible dans le document PDF, Image available in the PDF document] Compound 1E (3.1 g, 8.76 mmol) was dissolved in 30 mL of EtOH, and iron powder (2.94 g, 52.57 mmol) and an aqueous solution of ammonium chloride (4.69 g of ammonium chloride dissolved in 10 mL of water) were added. Under the protection of nitrogen gas, the reaction was carried out at 90 °C for 2 hours. After the reaction was completed, the reaction solution was filtered and the filtrate was concentrated to obtain compound 1F. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ=6.71<annotation encoding="application / x-tex">\delta = 6.71< / annotation>< / semantics>< / com:Math> (s, 1H), 6.66 (s, 1H), 4.73 (br s, 2H), 3.77 (s, 3H), 3.25 (m, 2H), 3.06 (m, 2H), 2.81 (m, 4H), 2.74 (s, 3H), 1.89 (m, 2H), 1.74 (m, 2H), 1.60 (m, 2H), 1.49 (m, 2H). Compound 1: [Image disponible dans le document PDF, Image available in the PDF document] Compound 1D (100 mg, 268.67 µmol) and compound 1F (87.01 mg, 268.67 µmol) were dissolved in 4 mL of tert-butanol, and added with methylsulphonicacid (103.28 mg, 1.07 mmol, 76.50 µL). The reaction was carried out at 90 °C for 12 hours. After the reaction was completed, the reaction solution was concentrated, adjusted to pH value of about 9 with saturated NaHCO<com:Sub>3< / com:Sub>, and extracted three times with DCM. The organic phases were collected, dried and concentrated to give a crude product. The crude product was purified by preparative HPLC to obtain compound 1 (40.16 mg, 63.98 µmol). <com:Sup>1< / com:Sup>H NMR (400MHz, MeOD) <com:Math><semantics>δ=8.54<annotation encoding="application / x-tex">\delta = 8.54< / annotation>< / semantics>< / com:Math> (br s, 1H), <com:Math><semantics>8.17<annotation encoding="application / x-tex">8.17< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=9.0<annotation encoding="application / x-tex">J = 9.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>8.09<annotation encoding="application / x-tex">8.09< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>8.02<annotation encoding="application / x-tex">8.02< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=5.6<annotation encoding="application / x-tex">J = 5.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.91 -7.80 (m, 3H), 6.74 (s, 1H), 3.88 (s, 3H), 3.30-3.16 (m, 4H), 2.96-2.88 (m, 4H), 2.84 (s, 3H), 1.99 (s, 3H)), 1.95 (s, 3H), 1.83 (br s, 3H), 1.73 (br s, 4H). Example 2 Compound 2A: [Image disponible dans le document PDF, Image available in the PDF document] Except for separate replacement of the compounds of 1-chloro-2-fluoro-4-methoxy-5-nitrobenzene and 3-methyl-3,9-diazaspiro[5.5]undecane with the compounds of 1-fluoro-5-methoxy-2-methyl-4-nitrobenzene and 2-methyl-2,7-diazaspiro[3.5]nonane, compound 2A was prepared according to the method for preparing compound 1E. Compound 2B: [Image disponible dans le document PDF, Image available in the PDF document] • Except for replacing compound 1E with compound 2A, compound 2B was prepared according to the method for preparing compound 1F. <com:Math><semantics>1H<annotation encoding="application / x-tex">^{1}H< / annotation>< / semantics>< / com:Math> NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=6.57<annotation encoding="application / x-tex">\delta = 6.57< / annotation>< / semantics>< / com:Math> (s, 1H), 6.53 (s, 1H), 4.64 (s, 1H), 3.86 -3.82 (m, 1H), 3.91-3.79 (m, 1H), 3.37 (s, 4H), <com:Math><semantics>2.78−2.69<annotation encoding="application / x-tex">2.78-2.69< / annotation>< / semantics>< / com:Math> (m, 4H), <com:Math><semantics>2.58−2.49<annotation encoding="application / x-tex">2.58-2.49< / annotation>< / semantics>< / com:Math> (m, 3H), <com:Math><semantics>2.19<annotation encoding="application / x-tex">2.19< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=15.8<annotation encoding="application / x-tex">J = 15.8< / annotation>< / semantics>< / com:Math> Hz, 3H), <com:Math><semantics>1.97−1.89<annotation encoding="application / x-tex">1.97-1.89< / annotation>< / semantics>< / com:Math> (m, 4H). Compound 2: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1F with compound 2B, compound 2 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR (400 MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 8.54 (br s, 1H), <com:Math><semantics>8.17 (d, J=9.0 Hz, 1H),8.09 (s, 1H),8.02 (d, J=5.6 Hz, 1H),7.91−7.80 (m, 3H),6.74 (s, 1H)<annotation encoding="application / x-tex">8.17 \text{ (d, } J = 9.0 \text{ Hz, } 1\text{H)}, 8.09 \text{ (s, } 1\text{H)}, 8.02 \text{ (d, } J = 5.6 \text{ Hz, } 1\text{H)}, 7.91-7.80 \text{ (m, } 3\text{H)}, 6.74 \text{ (s, } 1\text{H)}< / annotation>< / semantics>< / com:Math> 1H), 3.88 (s, 3H), 3.30-3.16 (m, 4H), 2.96-2.88 (m, 4H), 2.84 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.83 (brs, 3H), 1.73 (br s, 4H). Example 3 Compound 3A: [Image disponible dans le document PDF, Image available in the PDF document] The compounds of tert-butyl 4-oxopiperidine-1-carboxylate (20 g, 100.38 mmol) and 1-methylpiperazine (12.06 g, 120.45 mmol, 13.36 mL) were dissolved in 200 mL of ethanol, and added with AcOH (6.03 g, 100.38 mmol, 5.74 mL) and NaBH(OAc)<com:Sub>3< / com:Sub> (42.55 g, 200.76 mmol). The reaction was performed at 20 °C for 12 hours. After the reaction was completed, the reaction was quenched by adding methanol (10 mL) and water (10 mL) and then extracted with ethyl acetate (500 mL). The organic phase was collected, dried and concentrated to give compound 3A. Compound 3B: [Image disponible dans le document PDF, Image available in the PDF document] Compound 3A (16 g, 56.46 mmol) was dissolved in HCl / MeOH (50 mL, 4M) and reacted at 0 °C for 12 hours. After the reaction was completed, the reaction solution was concentrated to give compound 3B. Compound 3C: [Image disponible dans le document PDF, Image available in the PDF document] Except for separate replacement of the compounds of 1-chloro-2-fluoro-4-methoxy-5-nitrobenzene and 3-methyl-3,9-diazaspiro[5.5]undecane with the compounds of 4-fluoro-2-methoxy-1-nitrobenzene and 1-methyl-4-(4-piperidinyl)piperazine, compound 3C was prepared according to the method for preparing compound 1E. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=8.02−7.88<annotation encoding="application / x-tex">\delta = 8.02-7.88< / annotation>< / semantics>< / com:Math> (m, 1H), 6.40 (dd, J = 2.5, 9.5 Hz, 1H), 6.29 (d, <com:Math><semantics>J<annotation encoding="application / x-tex">J< / annotation>< / semantics>< / com:Math> = 2.5 Hz, 1H), 3.99-3.84 (m, 5H), 3.26-2.86 (m, 4H), 2.65-2.41 <com:Math><semantics>(m,8H),2.29(s,3H),2.00−1.92(m,2H),1.59(dq,<math>J=4.0,12.0Hz,2H).<annotation encoding="application / x-tex">(m, 8H), 2.29 (s, 3H), 2.00-1.92 (m, 2H), 1.59 (dq, J = 4.0, 12.0 Hz, 2H).< / annotation>< / semantics>< / com:Math> 5 Compound 3D: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1E with compound 3C, compound 3D was prepared according to the method for preparing compound 1F. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=6.56<annotation encoding="application / x-tex">\delta = 6.56< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(d,J=8.3 Hz,1H),6.45(d,J=2.4 Hz,1H),6.34(dd,J=2.4,8.6 Hz,1H),3.76(s,3H),3.45<annotation encoding="application / x-tex">(d, J = 8.3 \text{ Hz}, 1\text{H}), 6.45 (d, J = 2.4 \text{ Hz}, 1\text{H}), 6.34 (dd, J = 2.4, 8.6 \text{ Hz}, 1\text{H}), 3.76 (s, 3\text{H}), 3.45< / annotation>< / semantics>< / com:Math> (br d, <com:Math><semantics>J=12.2<annotation encoding="application / x-tex">J = 12.2< / annotation>< / semantics>< / com:Math> Hz, 3H), 2.75-2.47 (m, 7H), 2.46-2.36 (m, 3H), 2.31-2.20 (m, 5H), 1.85 (br d, <com:Math><semantics>J=12.5 Hz,2H,1.64(dq,<math>J=3.8,12.0 Hz,2H).<annotation encoding="application / x-tex">J = 12.5 \text{ Hz}, 2\text{H}, 1.64 (dq, J = 3.8, 12.0 \text{ Hz}, 2\text{H}).< / annotation>< / semantics>< / com:Math> Compound 3: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1F with compound 3D, compound 3 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR (400MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ=8.14<annotation encoding="application / x-tex">\delta = 8.14< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 1H), 8.04-7.87 (m, 4H), 7.36 (br d, <com:Math><semantics>J=8.6<annotation encoding="application / x-tex">J = 8.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.59 (d, <com:Math><semantics>J=2.2<annotation encoding="application / x-tex">J = 2.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.98 (br d, J <com:Math><semantics>=8.1 Hz,1H<annotation encoding="application / x-tex">= 8.1 \text{ Hz}, 1\text{H}< / annotation>< / semantics>< / com:Math>), 3.83 (s, 3H), 3.64-3.57 (m, 3H), 2.96-2.56 (m, 10H), 2.47 (s, 4H), 2.02 (br d, J <com:Math><semantics>=12.5 Hz,2H,1.95 (s, 3H),1.91 (s, 3H),1.71−1.60 (m, 2H).<annotation encoding="application / x-tex">= 12.5 \text{ Hz}, 2\text{H}, 1.95 \text{ (s, 3H)}, 1.91 \text{ (s, 3H)}, 1.71-1.60 \text{ (m, 2H)}.< / annotation>< / semantics>< / com:Math> Example 4 Compound 4A: [Image disponible dans le document PDF, Image available in the PDF document] Under the protection of nitrogen gas, naphthalene-2-amine (4 g, 27.94 mmol) was dissolved in a mixed solution of 120 mL DCM and 40 mL MeOH, and added with benzyltrimethylammonium dichloroiodide (9.72 g, 27.94 mmol). The reaction solution was reacted at 20 °C for 0.5 hours. After the reaction was completed, the reaction solution was washed with sodium bicarbonate solution, and the organic phase was collected and concentrated to obtain a crude product. The crude product was purified by column chromatography to give compound 4A. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=8.00<annotation encoding="application / x-tex">\delta = 8.00< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.4<annotation encoding="application / x-tex">J = 8.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.66 (dd, <com:Math><semantics>J=8.3<annotation encoding="application / x-tex">J = 8.3< / annotation>< / semantics>< / com:Math>, 17.6 Hz, 2H), 7.54 (ddd, <com:Math><semantics>J=1.2<annotation encoding="application / x-tex">J = 1.2< / annotation>< / semantics>< / com:Math>, 7.2, 8.4 Hz, 1H), 7.37-7.29 (m, 1H), <com:Math><semantics>6.99(d,J=8.8Hz,1H),4.47(brs,2H).<annotation encoding="application / x-tex">6.99 (d, J = 8.8 Hz, 1H), 4.47 (br s, 2H).< / annotation>< / semantics>< / com:Math> Compound 4B: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1B with compound 4A, compound 4B was prepared according to the method for preparing compound 1C. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=7.66<annotation encoding="application / x-tex">\delta = 7.66< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(d,J=8.8 Hz,2H),7.51−7.45 (m, 1H),7.45−7.37 (m, 1H),7.25−7.17 (m, 1H),6.76 (dd, J=8.8 Hz,2H)<annotation encoding="application / x-tex">(d, J = 8.8 \text{ Hz}, 2H), 7.51-7.45 \text{ (m, 1H)}, 7.45-7.37 \text{ (m, 1H)}, 7.25-7.17 \text{ (m, 1H)}, 6.76 \text{ (dd, } J = 8.8 \text{ Hz}, 2H)< / annotation>< / semantics>< / com:Math> 3.6, 8.8 Hz, 1H), 6.51 (br s, 2H), 2.05 (s, 3H), 2.01 (s, 2H); LC-MS (ESI): m / z: 220.1 [M+1]. Compound 4C: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1C with compound 4B, compound 4C was prepared according to the method for preparing compound 1D. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.05 (s, 1H), 8.62 (dd, <com:Math><semantics>J=4.0<annotation encoding="application / x-tex">J = 4.0< / annotation>< / semantics>< / com:Math>, 9.2 Hz, 1H), 8.24 (s, 1H), 8.04 (d, <com:Math><semantics>J=9.6<annotation encoding="application / x-tex">J = 9.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.89 (d, <com:Math><semantics>J=9.6<annotation encoding="application / x-tex">J = 9.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.89 (d, <com:Math><semantics>J=9.6<annotation encoding="application / x-tex">J = 9.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.89 (d, <com:Math><semantics>J=9.6<annotation encoding="application / x-tex">J = 9.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.89 (d, <com:Math><semantics>J=9.6<annotation encoding="application / x-tex">J = 9.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.89 (d, <com:Math><semantics>J=9.6<annotation encoding="application / x-tex">J = 9.6< / annotation>< / semantics>< / com:Math> <com:Math><semantics>=8.0 Hz,1H,7.71 (d, J=8.4 Hz,1H),7.56 (dd, J=7.2,7.2 Hz,1H),7.48 (dd, J=7.2,7.2 Hz,1H)<annotation encoding="application / x-tex">= 8.0 \text{ Hz}, 1\text{H}, 7.71 \text{ (d, } J = 8.4 \text{ Hz}, 1\text{H}), 7.56 \text{ (dd, } J = 7.2, 7.2 \text{ Hz}, 1\text{H}), 7.48 \text{ (dd, } J = 7.2, 7.2 \text{ Hz}, 1\text{H})< / annotation>< / semantics>< / com:Math> Hz, 1H), 2.18 (s, 3H), 2.14 (s, 3H). Compound 4: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1D with compound 4C, compound 4 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR (400MHz, MeOD) <com:Math><semantics>δ=8.45<annotation encoding="application / x-tex">\delta = 8.45< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>8.24−8.17<annotation encoding="application / x-tex">8.24-8.17< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>8.11<annotation encoding="application / x-tex">8.11< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>8.06<annotation encoding="application / x-tex">8.06< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=9.2<annotation encoding="application / x-tex">J = 9.2< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>7.98<annotation encoding="application / x-tex">7.98< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>7.91<annotation encoding="application / x-tex">7.91< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.63 (ddd, <com:Math><semantics>J=1.2<annotation encoding="application / x-tex">J = 1.2< / annotation>< / semantics>< / com:Math>, 7.2, 7.2 Hz, 1H), 7.53 (dd, <com:Math><semantics>J=7.2<annotation encoding="application / x-tex">J = 7.2< / annotation>< / semantics>< / com:Math>, 7.2 Hz, 1H), 6.75 (s, 1H), 3.89 (s, 3H), 3.32-3.12 (m, 4H), 2.98-2.90 (m, 4H), 2.88 (s, 3H), 2.14 (s, 3H), 2.10 (s, 3H), 2.05-1.49 (m, 8H); LC-MS (ESI): m / z: 653.0 [M+1]. Example 5 Compound 5: [Image disponible dans le document PDF, Image available in the PDF document] Except for respectively replacing compounds 1D and 1F with compounds 4C and 2B, compound 5 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR <com:Math><semantics>(400MHz,CD3OD)δ=8.56 (br s, 1H),8.30−8.21 (m, 2H),8.06 (s, 1H),8.02 (d, J=9.2 Hz,<annotation encoding="application / x-tex">(400MHz, CD_3OD) \delta = 8.56 \text{ (br s, 1H)}, 8.30-8.21 \text{ (m, 2H)}, 8.06 \text{ (s, 1H)}, 8.02 \text{ (d, } J = 9.2 \text{ Hz,}< / annotation>< / semantics>< / com:Math> 1H), 7.96 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.67-7.61 (m, 1H), 7.61-7.53 (m, 2H), 6.62 (d, <com:Math><semantics>J=2.0<annotation encoding="application / x-tex">J = 2.0< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>6.11<annotation encoding="application / x-tex">6.11< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=8.8<annotation encoding="application / x-tex">J = 8.8< / annotation>< / semantics>< / com:Math> Hz, 1H), <com:Math><semantics>3.87<annotation encoding="application / x-tex">3.87< / annotation>< / semantics>< / com:Math> (s, 4H), <com:Math><semantics>3.84<annotation encoding="application / x-tex">3.84< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>3.09−2.97<annotation encoding="application / x-tex">3.09-2.97< / annotation>< / semantics>< / com:Math> (m, 4H), <com:Math><semantics>2.88<annotation encoding="application / x-tex">2.88< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>2.10<annotation encoding="application / x-tex">2.10< / annotation>< / semantics>< / com:Math> (s, 3H), 2.07 (s, 3H), 2.04-1.94 (m, 4H); LCMS (ESI): m / z: 591.1 [M+1]. Example 6 Compound 6: [Image disponible dans le document PDF, Image available in the PDF document] Except for respectively replacing compounds 1D and 1F with compounds 4C and 3D, compound 6 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR <com:Math><semantics>(400MHz,CD3OD)δ=8.54 (br s, 1H),8.30−8.22 (m, 2H),8.06 (s, 1H),8.02 (d, J=9.2 Hz,)<annotation encoding="application / x-tex">(400MHz, CD_3OD) \delta = 8.54 \text{ (br s, 1H)}, 8.30-8.22 \text{ (m, 2H)}, 8.06 \text{ (s, 1H)}, 8.02 \text{ (d, } J = 9.2 \text{ Hz,})< / annotation>< / semantics>< / com:Math> 1H), 7.97 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.67-7.62 (m, 1H), 7.60-7.49 (m, 2H), 6.63 (d, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.13 (d, <com:Math><semantics>J=8.0<annotation encoding="application / x-tex">J = 8.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 3.85 (s, 3H), 3.63 (d, <com:Math><semantics>J=12.4<annotation encoding="application / x-tex">J = 12.4< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.79 (br s, 6H), 2.71-2.61 (m, 3H), 2.61-2.38 (m, 5H), 2.11 (s, 3H), 2.07 (s, 3H), 2.02 (br d, <com:Math><semantics>J=12.8<annotation encoding="application / x-tex">J = 12.8< / annotation>< / semantics>< / com:Math> Hz, 2H), 1.72-1.61 (m, 2H); LCMS (ESI): m / z: 634.1 [M+1]. Example 7 Compound 7A: [Image disponible dans le document PDF, Image available in the PDF document] 7-Nitroquinoline (7 g, 40.19 mmol) was dissolved in 120 mL of methanol, and added with Pd / C (10%, 1 g) under nitrogen atmosphere. After purged with hydrogen 3 times, the reaction solution was stirred at 20 °C under hydrogen atmosphere for 12 hours. After the reaction was completed, the reaction mixture was filtered and the filtrate was concentrated to give compound 7A. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=8.75<annotation encoding="application / x-tex">\delta = 8.75< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=1.8,4.3<annotation encoding="application / x-tex">J = 1.8, 4.3< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.98 (dd, <com:Math><semantics>J=0.8,8.0 Hz,1H,7.61 (d,J=8.8 Hz,1H),7.22 (d,J=2.3 Hz,1H),7.13 (dd,J=4.4,8.2)<annotation encoding="application / x-tex">J = 0.8, 8.0 \text{ Hz}, 1\text{H}, 7.61 \text{ (d}, J = 8.8 \text{ Hz}, 1\text{H}), 7.22 \text{ (d}, J = 2.3 \text{ Hz}, 1\text{H}), 7.13 \text{ (dd}, J = 4.4, 8.2)< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.98 (dd, <com:Math><semantics>J=2.3<annotation encoding="application / x-tex">J = 2.3< / annotation>< / semantics>< / com:Math>, 8.5 Hz, 1H), 3.98 (br s, 2H). Compound 7B: [Image disponible dans le document PDF, Image available in the PDF document] Compound 7A (2.5 g, 17.34 mmol) was dissolved in 75 mL of AcOH, and ICl (3.10 g, 19.07 mmol, 973.85 µL) was dissolved in 25 mL of acetic acid, which was added dropwise to the reaction solution. The reaction was stirred at 20 °C for 1 hour. After the reaction was completed, the reaction solution was subjected to rotary evaporation to remove acetic acid, and the residue was extracted with ethyl acetate and diluted, and then washed successively with water and saturated brine. The organic phase was collected, dried and concentrated to give a crude product. The crude product was purified by column chromatography to give compound 7B. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=8.88<annotation encoding="application / x-tex">\delta = 8.88< / annotation>< / semantics>< / com:Math> (dd, <com:Math><semantics>J=1.5<annotation encoding="application / x-tex">J = 1.5< / annotation>< / semantics>< / com:Math>, 4.3 Hz, 1H), 7.95 (dd, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> 1.5, 8.0 Hz, 1H), 7.58 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.21 (dd, <com:Math><semantics>J=4.3<annotation encoding="application / x-tex">J = 4.3< / annotation>< / semantics>< / com:Math>, 8.0 Hz, 1H), 7.04 (d, <com:Math><semantics>J=8.5<annotation encoding="application / x-tex">J = 8.5< / annotation>< / semantics>< / com:Math> Hz, 1H), 5.10-4.63 (m, 2H). Compound 7C: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1B with compound 7B, compound 7C was prepared according to the method for preparing compound 1C. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=8.63<annotation encoding="application / x-tex">\delta = 8.63< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(dd,J=1.8,4.3 Hz,1H),7.88 (td,J=1.5,7.9 Hz,1H),7.61 (d,J=9.0 Hz,1H),7.10 (dd,J=1.8,4.3 Hz,1H)<annotation encoding="application / x-tex">(dd, J = 1.8, 4.3 \text{ Hz}, 1H), 7.88 \text{ (td}, J = 1.5, 7.9 \text{ Hz}, 1H), 7.61 \text{ (d}, J = 9.0 \text{ Hz}, 1H), 7.10 \text{ (dd}, J = 1.8, 4.3 \text{ Hz}, 1H)< / annotation>< / semantics>< / com:Math> 4.4, 8.1 Hz, 1H), 6.80 (dd, <com:Math><semantics>J=3.9<annotation encoding="application / x-tex">J = 3.9< / annotation>< / semantics>< / com:Math>, 8.8 Hz, 1H), 6.73-6.23 (m, 1H), 2.07 (s, 3H), 2.03 (s, 3H). Compound 7D: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1C with compound 7C, compound 7D was prepared according to the method for preparing compound 1D. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.31 (s, 1H), 8.93 (dd, <com:Math><semantics>J=3.9<annotation encoding="application / x-tex">J = 3.9< / annotation>< / semantics>< / com:Math>, 9.2 Hz, 1H), 8.82 (dd, <com:Math><semantics>J=1.8<annotation encoding="application / x-tex">J = 1.8< / annotation>< / semantics>< / com:Math>, 4.3 Hz, 1H), 8.27 (s, 1H), 8.14 <com:Math><semantics>(d,J=8.3 Hz,1H),8.01(d,J=9.3 Hz,1H),7.38(dd,J=4.3,8.3 Hz,1H),2.19(s,3H),2.15<annotation encoding="application / x-tex">(d, J = 8.3 \text{ Hz}, 1\text{H}), 8.01 (d, J = 9.3 \text{ Hz}, 1\text{H}), 7.38 (dd, J = 4.3, 8.3 \text{ Hz}, 1\text{H}), 2.19 (s, 3\text{H}), 2.15< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(s,3H)<annotation encoding="application / x-tex">(s, 3H)< / annotation>< / semantics>< / com:Math>. Compound 7: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 3D with compound 7D, compound 7 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR (400MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ=8.92−8.79<annotation encoding="application / x-tex">\delta = 8.92-8.79< / annotation>< / semantics>< / com:Math> (m, 2H), 8.50 (br s, 1H), 8.23 (br d, <com:Math><semantics>J=8.3<annotation encoding="application / x-tex">J = 8.3< / annotation>< / semantics>< / com:Math> Hz, 1H), 8.07 (s, 1H), 7.90 (d, <com:Math><semantics>J=9.3<annotation encoding="application / x-tex">J = 9.3< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.69 <com:Math><semantics>(d,J=8.6 Hz,1H),7.43 (dd,J=4.3,8.2 Hz,1H),6.69 (d,J=2.4 Hz,1H),6.53 (dd,J=2.4,1Hz)<annotation encoding="application / x-tex">(d, J = 8.6 \text{ Hz}, 1\text{H}), 7.43 \text{ } (dd, J = 4.3, 8.2 \text{ Hz}, 1\text{H}), 6.69 \text{ } (d, J = 2.4 \text{ Hz}, 1\text{H}), 6.53 \text{ } (dd, J = 2.4, 1\text{Hz})< / annotation>< / semantics>< / com:Math> 8.8 Hz, 1H), 3.85 (s, 3H), 3.74 (br d, <com:Math><semantics>J=12.2<annotation encoding="application / x-tex">J = 12.2< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.99 -2.65 (m, 10H), 2.62-2.56 (m, 1H), 2.55 (s, 3H), 2.16 (s, 3H), 2.12 (s, 3H), 2.04 (br d, <com:Math><semantics>J=12.5<annotation encoding="application / x-tex">J = 12.5< / annotation>< / semantics>< / com:Math> Hz, 2H), 1.76-1.65 (m, 2H). Example 8 Compound 8A: [Image disponible dans le document PDF, Image available in the PDF document] 4-Nitrobenzene-1,2-diamine (10 g, 65.30 mmol) was dissolved in 100 mL of ethanol and added with glyoxal (4.55 g, 78.36 mmol, 4.10 mL), with stirring at 80 °C for 15 hours. After the reaction was completed, the mixture was filtered and the filter cake was dried to give compound 10A. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ=9.18<annotation encoding="application / x-tex">\delta = 9.18< / annotation>< / semantics>< / com:Math> (s, 2H), 8.93 (d, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 8.58 (dd, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math>, 9.2 Hz, 1H), 8.36 (d, <com:Math><semantics>J=9.2<annotation encoding="application / x-tex">J = 9.2< / annotation>< / semantics>< / com:Math> Hz, 1H); LC-MS (ESI) : m / z: 176.1 <com:Math><semantics>[M+1].<annotation encoding="application / x-tex">[M+1].< / annotation>< / semantics>< / com:Math> Compound 8B: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1E with compound 8A, compound 8B was prepared according to the method for preparing compound 1F. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ=<annotation encoding="application / x-tex">\delta =< / annotation>< / semantics>< / com:Math> <com:Math><semantics>8.60(d,J=1.6Hz,1H),8.45(d,J=1.6Hz,1H),7.73(d,J=9.2Hz,1H),7.24(dd,J=2.4,1H)<annotation encoding="application / x-tex">8.60 (d, J = 1.6 Hz, 1H), 8.45 (d, J = 1.6 Hz, 1H), 7.73 (d, J = 9.2 Hz, 1H), 7.24 (dd, J = 2.4, 1H)< / annotation>< / semantics>< / com:Math> 9.2 Hz, 1H), 6.92 (d, <com:Math><semantics>J=2.4<annotation encoding="application / x-tex">J = 2.4< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.08 (s, 2H). LC-MS (ESI): m / z: 146.2 [M+1]. Compound 8C: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 7A with compound 8B, compound 8C was prepared according to the method for preparing compound 7B. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ=<annotation encoding="application / x-tex">\delta =< / annotation>< / semantics>< / com:Math> 8.76 (d, <com:Math><semantics>J=1.6<annotation encoding="application / x-tex">J = 1.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 8.56 (d, <com:Math><semantics>J=1.6<annotation encoding="application / x-tex">J = 1.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.80 (d, <com:Math><semantics>J=9.2<annotation encoding="application / x-tex">J = 9.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.45 (d, <com:Math><semantics>J=9.2<annotation encoding="application / x-tex">J = 9.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.38 (br s, 2H). LC-MS (ESI): m / z: 271.9 [M+1]. Compound 8D: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1B with compound 8C, compound 8D was prepared according to the method for preparing compound 1C. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ=<annotation encoding="application / x-tex">\delta =< / annotation>< / semantics>< / com:Math> 8.61 (d, <com:Math><semantics>J=1.6<annotation encoding="application / x-tex">J = 1.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 8.49 (d, <com:Math><semantics>J=1.6<annotation encoding="application / x-tex">J = 1.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.82 (d, <com:Math><semantics>J=9.2<annotation encoding="application / x-tex">J = 9.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.22 (d, <com:Math><semantics>J=9.2<annotation encoding="application / x-tex">J = 9.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.38 (br s, 2H), 1.89 (s, 3H), 1.85 (s, 3H). LC-MS (ESI): m / z: 222.1 [M+1]. Compound 8E: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1C with compound 8D, compound 8E was prepared according to the method for preparing compound 1D. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ<annotation encoding="application / x-tex">\delta< / annotation>< / semantics>< / com:Math> = 13.20 (s, 1H), 9.12 (dd, <com:Math><semantics>J=4.0<annotation encoding="application / x-tex">J = 4.0< / annotation>< / semantics>< / com:Math>, 9.6 Hz, 1H), 8.75 (s, 1H), 8.68 (s, 1H), 8.23 (s, 1H), 8.21 (d, <com:Math><semantics>J=9.6 Hz<annotation encoding="application / x-tex">J = 9.6 \text{ Hz}< / annotation>< / semantics>< / com:Math>, 1H), 2.08 (s, 3H), 2.05 (s, 3H); LC-MS (ESI): m / z: 367.9 [M+1]. Compound 8: [Image disponible dans le document PDF, Image available in the PDF document] Except for respectively replacing compounds 1D and 1F with compounds 8E and 2B, compound 8 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR <com:Math><semantics>(400MHz,DMSO−d6)δ=12.90(s,1H),9.09−8.96(m,1H),8.87(dd,J=2.0,7.6Hz,2H),<annotation encoding="application / x-tex">(400MHz, DMSO-d_6) \delta = 12.90 (s, 1H), 9.09-8.96 (m, 1H), 8.87 (dd, J = 2.0, 7.6 Hz, 2H),< / annotation>< / semantics>< / com:Math> 8.31-8.24 (m, 2H), 8.20 (s, 1H), 7.93 (d, <com:Math><semantics>J=9.2<annotation encoding="application / x-tex">J = 9.2< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.37 (s, 1H), 6.74 (s, 1H), 3.78 (s, 3H), 3.10 (s, 4H), 2.77 (t, <com:Math><semantics>J=5.2<annotation encoding="application / x-tex">J = 5.2< / annotation>< / semantics>< / com:Math> Hz, 4H), 2.33 (s, 3H), 2.12 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 1.84 (t, <com:Math><semantics>J=5.2<annotation encoding="application / x-tex">J = 5.2< / annotation>< / semantics>< / com:Math> Hz, 4H); LC-MS (ESI): m / z: 607.1 [M+1]. Example 9 Compound 9: [Image disponible dans le document PDF, Image available in the PDF document] Except for respectively replacing compounds 1D and 1F with compounds 4C and 2B, compound 9 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR <com:Math><semantics>(400MHz,CD3OD)δ=8.57(s,1H),8.27(d,J=8.8Hz,1H),8.24−8.19(m,1H),8.08(s,1H),<annotation encoding="application / x-tex">(400MHz, CD_3OD) \delta = 8.57 (s, 1H), 8.27 (d, J = 8.8 Hz, 1H), 8.24-8.19 (m, 1H), 8.08 (s, 1H),< / annotation>< / semantics>< / com:Math> 8.00 (d, <com:Math><semantics>J=9.1<annotation encoding="application / x-tex">J = 9.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.93 (d, <com:Math><semantics>J=7.7<annotation encoding="application / x-tex">J = 7.7< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.68-7.53 (m, 3H), 6.65 (s, 1H), 3.84 (s, 3H), 3.58-3.50 (m, 4H), 2.79-2.71 (m, 4H), 2.66 (s, 3H), 2.12 (s, 3H), 2.09 (s, 3H), 1.98-1.90 (m, 4H), 1.79 (s, 3H). Example 10 Compound 10: [Image disponible dans le document PDF, Image available in the PDF document] - Except for replacing compound 1D with compound 7D, compound 10 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR (400MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ=8.83<annotation encoding="application / x-tex">\delta = 8.83< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(dd,J=1.7,4.4 Hz,1H),8.71(dd,J=3.7,9.0 Hz,1H),8.49(brs,1H),8.20(brd,J=8.1 Hz,1Hz)<annotation encoding="application / x-tex">(dd, J = 1.7, 4.4 \text{ Hz}, 1\text{H}), 8.71 (dd, J = 3.7, 9.0 \text{ Hz}, 1\text{H}), 8.49 (br s, 1\text{H}), 8.20 (br d, J = 8.1 \text{ Hz}, 1\text{Hz})< / annotation>< / semantics>< / com:Math> 1H), 8.11 (s, 1H), 8.06 (s, 1H), 8.00 (d, <com:Math><semantics>J=9.3<annotation encoding="application / x-tex">J = 9.3< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.43 (dd, <com:Math><semantics>J=4.3<annotation encoding="application / x-tex">J = 4.3< / annotation>< / semantics>< / com:Math>, 8.2 Hz, 1H), 6.78 (s, 1H), 3.89 (s, 3H), 3.24 (br s, 4H), 3.04-2.92 (m, 4H), 2.86 (s, 3H), 2.16 (s, 3H), 2.12 (s, 3H), 1.93-1.59 (m, 8H). Example 11 5 Compound 11A: [Image disponible dans le document PDF, Image available in the PDF document] / Except for respectively replacing the compounds of 1-chloro-2-fluoro-4-methoxy-5-nitrobenzene and 3-methyl-3,9-diazaspiro[5.5]undecane with the compounds of 1-chloro-2-fluoro-4-methoxy-5-nitrobenzene and 1-methyl-4-(piperidin-4-yl)piperazine, compound 11A was prepared according to the method for preparing compound 1E. <com:Sup>1< / com:Sup>H NMR (400MHz, CD<com:Sub>3< / com:Sub>OD) <com:Math><semantics>δ=6.79<annotation encoding="application / x-tex">\delta = 6.79< / annotation>< / semantics>< / com:Math> (s, 1H), 6.68 (s, 1H), <com:Math><semantics>3.84<annotation encoding="application / x-tex">3.84< / annotation>< / semantics>< / com:Math> (s, <com:Math><semantics>3H<annotation encoding="application / x-tex">3H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>3.24−2.76<annotation encoding="application / x-tex">3.24-2.76< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>8H<annotation encoding="application / x-tex">8H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.72<annotation encoding="application / x-tex">2.72< / annotation>< / semantics>< / com:Math> (br s, <com:Math><semantics>1H<annotation encoding="application / x-tex">1H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.71−2.65<annotation encoding="application / x-tex">2.71-2.65< / annotation>< / semantics>< / com:Math> (m, <com:Math><semantics>2H<annotation encoding="application / x-tex">2H< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>2.02<annotation encoding="application / x-tex">2.02< / annotation>< / semantics>< / com:Math> (br d, <com:Math><semantics>J=10.8<annotation encoding="application / x-tex">J = 10.8< / annotation>< / semantics>< / com:Math> Hz, 2H), 1.89-1.71 (m, 2H). 15 Compound 11B: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1E with compound 11A, compound 11B was prepared according to the method for preparing compound 1F. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=8.04<annotation encoding="application / x-tex">\delta = 8.04< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>6.56<annotation encoding="application / x-tex">6.56< / annotation>< / semantics>< / com:Math> (s, 1H), <com:Math><semantics>4.02−3.91<annotation encoding="application / x-tex">4.02-3.91< / annotation>< / semantics>< / com:Math> (m, 3H), <com:Math><semantics>3.65<annotation encoding="application / x-tex">3.65< / annotation>< / semantics>< / com:Math> (br d, <com:Math><semantics>J=12.1<annotation encoding="application / x-tex">J = 12.1< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>2.81−2.73<annotation encoding="application / x-tex">2.81-2.73< / annotation>< / semantics>< / com:Math> (m, 2H), <com:Math><semantics>2.66<annotation encoding="application / x-tex">2.66< / annotation>< / semantics>< / com:Math> (br s, 4H), <com:Math><semantics>2.56−2.37<annotation encoding="application / x-tex">2.56-2.37< / annotation>< / semantics>< / com:Math> (m, 5H), <com:Math><semantics>2.31<annotation encoding="application / x-tex">2.31< / annotation>< / semantics>< / com:Math> (s, 3H), <com:Math><semantics>1.98<annotation encoding="application / x-tex">1.98< / annotation>< / semantics>< / com:Math> (br d, <com:Math><semantics>J=12.2<annotation encoding="application / x-tex">J = 12.2< / annotation>< / semantics>< / com:Math> Hz, 2H), <com:Math><semantics>1.84−1.71<annotation encoding="application / x-tex">1.84-1.71< / annotation>< / semantics>< / com:Math> (m, 2H). Compound 11: [Image disponible dans le document PDF, Image available in the PDF document] Except for separately replacing compounds 1D and 1F with compounds 4C and 11B, compound 11 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR <Formule mathématique disponible dans le document PDF, Math available in the PDF document>(400MHz, CD_3OD) \delta = 8.23 \text{ (br d, } J = 8.7 \text{ Hz, } 2H), 8.16-8.10 \text{ (m, } 1H), 8.02 \text{ (br d, } J = 8.1 \text{ Hz, } 3.1 \text{ Hz, } 3.1 \text{ Hz, } 3.1 \text{ Hz, } 3.1 \text{ Hz, } 3.1 \text{ Hz, } 3.1 \text{ Hz, } 3.1 \text{ Hz, } 3.1 \text{ Hz, 1H), 7.76-7.55 (m, 3H), 6.85 (s, 1H), 4.01 (br s, 2H), 3.92 (s, 5H), 3.73 (br s, 3H), 3.69-3.56 (m, 2H), 3.50 (br d, <com:Math><semantics>J=10.1<annotation encoding="application / x-tex">J = 10.1< / annotation>< / semantics>< / com:Math> Hz, 2H), 3.08 (s, 3H), 2.86 (br t, <com:Math><semantics>J=11.5<annotation encoding="application / x-tex">J = 11.5< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.36 (br d, <com:Math><semantics>J=10.1<annotation encoding="application / x-tex">J = 10.1< / annotation>< / semantics>< / com:Math> Hz, 2H), 3.08 (s, 3H), 2.86 (br t, <com:Math><semantics>J=10.5<annotation encoding="application / x-tex">J = 10.5< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.36 (br d, <com:Math><semantics>J=10.5<annotation encoding="application / x-tex">J = 10.5< / annotation>< / semantics>< / com:Math> Hz, 2H), 2.36 (br d, <com:Math><semantics>J=10.5<annotation encoding="application / x-tex">J = 10.5< / annotation>< / semantics>< / com:Math> H <com:Math><semantics>=11.5 Hz,2H),2.17 (s, 3H),2.14 (s, 3H),2.11−2.02 (m, 2H).<annotation encoding="application / x-tex">= 11.5 \text{ Hz}, 2\text{H}), 2.17 \text{ (s, 3H)}, 2.14 \text{ (s, 3H)}, 2.11-2.02 \text{ (m, 2H)}.< / annotation>< / semantics>< / com:Math> Example 12 Compound 12: [Image disponible dans le document PDF, Image available in the PDF document] Except for respectively replacing compounds 1D and 1F with compounds 2B and 7D, compound 12 was prepared according to the method for preparing compound 1. <com:Sup>1< / com:Sup>H NMR <com:Math><semantics>(400MHz,CD3OD)δ=8.84 (br d, J=2.7 Hz, 1H),8.79 (br dd, J=3.7,9.0 Hz, 1H),8.50 (br dd)<annotation encoding="application / x-tex">(400MHz, CD_3OD) \delta = 8.84 \text{ (br d, } J = 2.7 \text{ Hz, } 1\text{H}), 8.79 \text{ (br dd, } J = 3.7, 9.0 \text{ Hz, } 1\text{H}), 8.50 \text{ (br dd)}< / annotation>< / semantics>< / com:Math> s, 1H), 8.22 (br d, <com:Math><semantics>J=8.1<annotation encoding="application / x-tex">J = 8.1< / annotation>< / semantics>< / com:Math> Hz, 1H), 8.08 (s, 1H), 7.90 (br d, <com:Math><semantics>J=9.0<annotation encoding="application / x-tex">J = 9.0< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.74 (s, 1H), 7.44 <com:Math><semantics>(dd,J=4.3,8.2 Hz,1H),6.71 (s, 1H),4.01 (br s, 4H),3.84 (s, 3H),2.95 (s, 3H),2.82 (br s, 4H)<annotation encoding="application / x-tex">(dd, J = 4.3, 8.2 \text{ Hz}, 1\text{H}), 6.71 \text{ (s, 1H)}, 4.01 \text{ (br s, 4H)}, 3.84 \text{ (s, 3H)}, 2.95 \text{ (s, 3H)}, 2.82 \text{ (br s, 4H)}< / annotation>< / semantics>< / com:Math> 4H), 2.16 (s, 3H), 2.13 (s, 3H), 2.08 (s, 3H), 2.03 (br s, 4H). Example 13 Compound 13A: [Image disponible dans le document PDF, Image available in the PDF document] 6-Nitro-1H-indazole (25 g, 153.25 mmol) was dissolved in 200 mL of DMF, NaH (6.74 g, 168.57 mmol, 60% purity) was added in portions at 0 °C, and then MeI (23.93 g, 168.57 mmol, 10.49 mL) was added in portions at 0 °C. The reaction was performed at 25 °C for 1 hour. After the reaction was completed, the reaction solution was poured into 500 mL of water and extracted with EtOAc. The organic phase was collected and washed successively with 20 mL of water and 20 mL of saturated brine. The organic phase was collected, dried and concentrated to give a crude product. The crude product was purified by column chromatography to give compound 13A. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ=8.71<annotation encoding="application / x-tex">\delta = 8.71< / annotation>< / semantics>< / com:Math> (d, <com:Math><semantics>J=<annotation encoding="application / x-tex">J =< / annotation>< / semantics>< / com:Math> <com:Math><semantics>0.7 Hz<annotation encoding="application / x-tex">0.7 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1H<annotation encoding="application / x-tex">1\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>8.29 (d, J=0.7 Hz<annotation encoding="application / x-tex">8.29 \text{ (d, } J = 0.7 \text{ Hz}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1H<annotation encoding="application / x-tex">1\text{H}< / annotation>< / semantics>< / com:Math>), <com:Math><semantics>8.03−7.97 (m, 1H)<annotation encoding="application / x-tex">8.03 - 7.97 \text{ (m, 1H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7.96−7.92 (m, 1H)<annotation encoding="application / x-tex">7.96 - 7.92 \text{ (m, 1H)}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4.19 (s, 3H)<annotation encoding="application / x-tex">4.19 \text{ (s, 3H)}< / annotation>< / semantics>< / com:Math>. Compound 13B: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1E with compound 13A, compound 13B was prepared according to the method for preparing compound 1F. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ=<annotation encoding="application / x-tex">\delta =< / annotation>< / semantics>< / com:Math> 7.68 (s, 1H), 7.36 (d, <com:Math><semantics>J=8.6<annotation encoding="application / x-tex">J = 8.6< / annotation>< / semantics>< / com:Math> Hz, 1H), 6.50 (dd, <com:Math><semantics>J=2.0<annotation encoding="application / x-tex">J = 2.0< / annotation>< / semantics>< / com:Math>, 8.6 Hz, 1H), 6.45 (s, 1H), 5.32 (s, 2H), 3.81 (s, 3H). Compound 13C: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 7A with compound 13B, compound 13C was prepared according to the method for preparing compound 7B. <com:Sup>1< / com:Sup>H NMR (400MHz, CDCl<com:Sub>3< / com:Sub>) <com:Math><semantics>δ=7.76<annotation encoding="application / x-tex">\delta = 7.76< / annotation>< / semantics>< / com:Math> <com:Math><semantics>(s,1H),7.40(d,J=8.5Hz,1H),6.61(d,J=8.3Hz,1H),4.38(s,3H).<annotation encoding="application / x-tex">(s, 1H), 7.40 (d, J = 8.5 Hz, 1H), 6.61 (d, J = 8.3 Hz, 1H), 4.38 (s, 3H).< / annotation>< / semantics>< / com:Math> Compound 13D: [Image disponible dans le document PDF, Image available in the PDF document] Except for replacing compound 1B with compound 13C, compound 13D was prepared according to the method for preparing compound 1C. <com:Sup>1< / com:Sup>H NMR (400MHz, DMSO-<com:Math><semantics>d6<annotation encoding="application / x-tex">d_6< / annotation>< / semantics>< / com:Math>) <com:Math><semantics>δ=<annotation encoding="application / x-tex">\delta =< / annotation>< / semantics>< / com:Math> 7.81 (d, <com:Math><semantics>J=1.7<annotation encoding="application / x-tex">J = 1.7< / annotation>< / semantics>< / com:Math> Hz, 1H), 7.50 (dd, <com:Math><semantics>J=1.1<annotation encoding="application / x-tex">J = 1.1< / annotation>< / semantics>< / com:Math>, 8.7 Hz, 1H), 6.55 (dd, <com:Math><semantics>J=3.2<annotation encoding="application / x-tex">J = 3.2< / annotation>< / semantics>< / com:Math>, 8...

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, [Image disponible dans le document PDF, Image available in the PDF document] (I) , wherein, ring A is selected from phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, C 5 − 7 C_{5-7} cycloalkenyl and C 5 − 7 C_{5-7} cycloalkyl, wherein said phenyl, 5- to 6-membered heteroaryl, 5- to 7-membered heterocycloalkyl, C 5 − 7 C_{5-7} cycloalkenyl and C 5 − 7 C_{5-7} cycloalkyl are optionally substituted with R 6 ; [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] and the structural unit is not selected from: , R 1 R_1 is selected from H, halogen, C 1 − 6 C_{1-6} alkyl, C 1 − 6 C_{1-6} heteroalkyl, C 2 − 6 C_{2-6} alkenyloxy, and C 3 − 6 C_{3-6} cycloalkyloxy, wherein the C 1 − 6 C_{1-6} alkyl, C 1 − 6 C_{1-6} heteroalkyl, C 2 − 6 C_{2-6} alkenyloxy and C 3 − 6 C_{3-6} cycloalkyloxy are optionally substituted with 1, 2 or 3 R groups; R 2 is selected from H, halogen, CN, OH, NO 2 , NH 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-14 cycloalkyl, C 3-6 cycloalkenyl, C 4-6 cycloalkynyl, phenyl, and 3- to 14-membered heterocyclic groups, wherein said NH 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-14 cycloalkyl, C 3-6 cycloalkenyl, C 4-6 cycloalkynyl, phenyl and 3- to 14-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; R 3 R_3 is selected from H, halogen, C 1 − 6 C_{1-6} alkoxy, C 2 − 6 C_{2-6} alkenyloxy, C 3 − 6 C_{3-6} cycloalkyloxy, − O C ( = O ) N H 2 -OC(=O)NH_2 , − O C ( = O ) N H R -OC(=O)NHR , − O C ( = O ) N R R -OC(=O)NRR , − N R C ( = O ) O R -NRC(=O)OR , − N H C ( = O ) O R -NHC(=O)OR , − N H C ( = O ) O H -NHC(=O)OH , -O(CH 2 ) n NR a R b , C 1-6 alkyl, C 3-6 cycloalkyl and 5- to 6-membered heterocyclic group containing 1, 2, or 3 N or O atoms, wherein said C 1-6 alkyl, C 3-6 cycloalkyl, and 5- to 6-membered heterocyclic group containing 1, 2 or 3 N or O atoms are optionally substituted with 1, 2 or 3 R groups; n is selected from 0, 1, 2, 3 or 4; R a R_a and R b R_b are each independently selected from H, C 1 − 5 C_{1-5} alkyl and C 1 − 5 C_{1-5} heteroalkyl, and said C 1 − 5 C_{1-5} alkyl and C 1 − 5 C_{1-5} heteroalkyl are optionally substituted with 1, 2 or 3 R groups; or alternatively R a and R b are bonded together to form a 5- to 6-membered heterocyclic ring; R 4 and R 5 are each independently selected from H, halogen, CN, NH 2 , C 1-4 alkyl, C 1-4 heteroalkyl, C 3-6 cycloalkyl, phenyl, and 5- to 6-membered heterocyclic group, wherein said NH 2 , C 1-4 alkyl, C 1-4 heteroalkyl, C 3-6 cycloalkyl, phenyl and 5- to 6-membered heterocyclic group are optionally substituted with 1, 2 or 3 R groups; or alternatively, R 4 and R 5 are bonded together to form a 5- to 6-membered ring containing 1, 2, or 3 atoms independently selected from N, S or O, wherein the 5- to 6-membered ring is optionally substituted with 1, 2 or 3 R groups; each R 6 is independently selected from H, halogen, CN, OH, NH 2 , C 1-6 alkyl, C 1-6 heteroalkyl, = = O and = = S; R 7 R_7 and R 8 R_8 are each independently selected from H or C 1 − 6 C_{1-6} alkyl; or alternatively R 7 and R 8 are bonded together to form a 5- to 6-membered heterocyclic ring, and the 5- to 6-membered heterocyclic ring is optionally substituted with 1, 2 or 3 R groups; R is selected from halogen, CN, OH, NH 2 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3 − 6 C_{3-6} cycloalkenyl, C 4 − 6 C_{4-6} cycloalkynyl, C 1 − 6 C_{1-6} heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl, wherein said C 1 − 6 C_{1-6} alkyl, C 2 − 6 C_{2-6} alkenyl, C 2-6 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkenyl, C 4-6 cycloalkynyl, C 1-6 heteroalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl are optionally substituted with 1, 2 or 3 R' groups; R' is selected from H, F, Cl, Br, I, CN, OH, NH 2 , CH 3 , CH 3 CH 2 , CH 3 CH 2 , (CH 3 ) 2 CH, CH 3 O, CF 3 , CHF 2 and CH 2 F; "hetero" represents a heteroatom or a heteroatom group, and each "hetero" group in said 5- to 6-membered heterocyclic group, 5- to 6-membered heterocyclic ring, 5- to 7-membered heterocycloalkyl, 3- to 14-membered heterocyclic group, C 1-4 heteroalkyl, C 1-5 heteroalkyl, C 1 − 6 C_{1-6} heteroalkyl, 3- to 6-membered heterocycloalkyl, and 5- to 6-membered heteroaryl is independently selected from -C(=O)NH, -C(=NH)-, , -S(=O) 2 N(H)-, -S(=O)N(H)-, N, -NH-, − O − -O- , − S − -S- , − C ( = O ) O − -C(=O)O- , − C ( = O ) − -C(=O)- , − C ( = S ) − -C(=S)- , − S ( = O ) − -S(=O)- , and − S ( = O ) 2 − -S(=O)_2- ; in any one of the cases as described above, the number of the heteroatom or heteroatomic group is each independently selected from 1, 2, or 3.

2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R is selected from F, Cl, Br, I, CN, OH, NH 2 , CH 3 , CH 3 CH 2 , CH 3 CH 2 CH 2 , [Image disponible dans le document PDF, Image available in the PDF document]3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R 1 R_1 is selected from H, halogen, C 1 − 3 C_{1-3} alkyl, C 1 − 3 C_{1-3} heteroalkyl, C 2 − 5 C_{2-5} alkenyloxy, and C 4 − 6 C_{4-6} cycloalkyloxy, wherein said C 1 − 3 C_{1-3} alkyl, C 1 − 3 C_{1-3} heteroalkyl, C 2 − 5 C_{2-5} alkenyloxy and C 4 − 6 C_{4-6} cycloalkyloxy are optionally substituted with 1, 2, or 3 R groups.

4. The compound or the pharmaceutically acceptable salt thereof according to claim 3, wherein R 1 is selected from H, F, Cl, Br, I, CH 3 , CH 3 CH 2 , CH 3 CH 2 CH 2 , (CH 3 ) 2 CH, CH 3 O, CH 3 CH 2 O, CH 3 CH 2 CH 2 O, (CH 3 ) 2 CHO, on and wherein said CH 3 , [Image disponible dans le document PDF, Image available in the PDF document] ` CA3069829 [Image disponible dans le document PDF, Image available in the PDF document] and are optionally substituted with 1, 2 or 3 R groups.

5. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R 2 is selected from H, halogen, CN, OH, NO 2 , NH 2 , C 3-12 cycloalkyl, and 3- to 12-membered heterocycloalkyl, wherein said NH 2 , C 3-12 cycloalkyl and 3- to 12-membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R groups.

6. The compound or the pharmaceutically acceptable salt thereof according to claim 5, [Image disponible dans le document PDF, Image available in the PDF document] wherein R 2 is selected from H, halogen, CN, OH, NH 2 , NO 2 , -NHR, -N(R) 2 , [Image disponible dans le document PDF, Image available in the PDF document]7. The compound or the pharmaceutically acceptable salt thereof according to claim 6, [Image disponible dans le document PDF, Image available in the PDF document] wherein R 2 is selected from H, F, Cl, Br, CN, OH, NH 2 , NO 2 , CA3069829 [Image disponible dans le document PDF, Image available in the PDF document]8. The compound or thea pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R 6 is selected from H, F, Cl, Br, CN, OH, NH 2 , CH 3 , CH 3 CH 2 , CH 3 CH 2 CH 2 , ( C H 3 ) 2 C H (CH_3)_2CH , C H 3 O CH_3O , = S =S and = O =O .

9. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein ring A is selected from phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl, and pyrrolyl, wherein said phenyl, thienyl, pyridyl, pyrazinyl, pyrazolyl, cyclopentanonyl, cyclopentenyl, thiazolyl, isothiazolyl, and pyrrolyl are optionally substituted with R 6 .

10. The compound or the pharmaceutically acceptable salt thereof according to claim 9, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] wherein the structural unit is selected from [Image disponible dans le document PDF, Image available in the PDF document] . CA3069829 [Image disponible dans le document PDF, Image available in the PDF document] and •11. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R a and R b are each independently selected from H, CH 3 , CH 3 CH 2 , and -S(=O) 2 CH 3 , wherein said CH 3 , CH 3 CH 2 and -S(=O) 2 CH 3 are optionally substituted with 1, 2 or 3 R groups.

12. The compound or the pharmaceutically acceptable salt thereof according to claim 11, [Image disponible dans le document PDF, Image available in the PDF document] wherein R a and R b are each independently selected from H, and − S ( = O ) 2 C H 3 -S(=O)_2CH_3 .

13. The compound or the pharmaceutically acceptable salt thereof according to claim 12, [Image disponible dans le document PDF, Image available in the PDF document] wherein R 3 is selected from14. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, [Image disponible dans le document PDF, Image available in the PDF document] wherein R 3 is selected from H, F, Cl, Br, CH 3 , CH 3 CH 2 , (CH 3 ) 2 CH, and [Image disponible dans le document PDF, Image available in the PDF document]15. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R 5 is selected from H, F, Cl, Br, I, CN, CH 3 , CH 3 CH 2 , CH 3 CH 2 CH 2 , (CH 3 ) 2 CH, [Image disponible dans le document PDF, Image available in the PDF document]16. The compound or the pharmaceutically acceptable salt thereof according to claim 15, wherein R 5 is selected from H, Cl, Br, CN, CH 3 , CH 3 CH 2 , CH 3 CH 2 CH 2 , (CH 3 ) 2 CH, [Image disponible dans le document PDF, Image available in the PDF document]17. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 118. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R 7 and R 8 are each independently selected from H or CH 3 .

19. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 18, which is selected from [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] , , , , (AT) . • CA3069829 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (IIII) (IX) , , wherein, R 1 R_1 is as defined in any one of claims 1-4, R 2 R_2 is as defined in any one of claims 1-2 or 5-7, R 3 R_3 is as defined in any one of claims 1-2 or 13-14, R 4 is as defined in claims 1-2 or 17, R 5 R_5 is as defined in any one of claims 1-2 or 15-17, R 6 R_6 is as defined in any one of claims 1-2 or 8, R 7 and R 8 are as defined in any one of claims 1-2 or 18.

20. The compound or the pharmaceutically acceptable salt thereof according to claim 19, which is selected from [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] (V-1) (V-2) , , [Image disponible dans le document PDF, Image available in the PDF document] (V-3) , wherein R 1 , R 3 , R 4 , R 5 , R 7 , R 8 , R and R' are as defined in claim 19.

21. A compound or a pharmaceutically acceptable salt thereof, which is selected from [Image disponible dans le document PDF, Image available in the PDF document] • CA3069829 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] ∼ \sim i [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document]22. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21, and a pharmaceutically acceptable carrier.

23. Use of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21, or the pharmaceutical composition according to claim 22 in preparing a medicament for treating cancer.

24. Use of the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21, or the pharmaceutical composition according to claim 22 for treating cancer.

25. The use according to claim 23 or 24 in combination with an EGFR monoclonal antibody.

26. The use according to claim 25, wherein the EGFR monoclonal antibody is cetuximab.

27. The use according to claim 23 or 24 in combination with a MEK inhibitor.

28. The use according to any one of claims 23 to 27, wherein the cancer is lung cancer.

29. The compound or the pharmaceutically acceptable salt thereof according to any one of claims 1 to 21 or the pharmaceutical composition according to claim 22, for use in treating cancer.